[go: up one dir, main page]

WO2011085334A1 - Polymorphismes du cd44 prédisant le résultat clinique chez des patients atteints d'un cancer gastrique - Google Patents

Polymorphismes du cd44 prédisant le résultat clinique chez des patients atteints d'un cancer gastrique Download PDF

Info

Publication number
WO2011085334A1
WO2011085334A1 PCT/US2011/020718 US2011020718W WO2011085334A1 WO 2011085334 A1 WO2011085334 A1 WO 2011085334A1 US 2011020718 W US2011020718 W US 2011020718W WO 2011085334 A1 WO2011085334 A1 WO 2011085334A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
therapy
tissue
cell
genotype
Prior art date
Application number
PCT/US2011/020718
Other languages
English (en)
Inventor
Heinz-Josef Lenz
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Publication of WO2011085334A1 publication Critical patent/WO2011085334A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • CD44 POLYMORPHISMS PREDICT CLINICAL OUTCOME IN PATIENTS WITH
  • This invention relates to the field of pharmacogenomics and specifically to the application of genetic polymorphisms to diagnose and treat diseases.
  • Gastric cancer is the 4 th most common cancer type worldwide with 21 ,130 new diagnosed patients in the United States in 2009. National Cancer Institute data obtained from at cancer.gov/cancertopics/types/stomach. It is the 2 nd cause of cancer death with 10,620 deaths reported in the United States in 2009. National Cancer Institute data obtained from
  • CD44 is a transmembrane marker known to be expressed in diffuse and intestinal gastric cancers. Keller et al. (2005) Expert. Rev. Mol. Med. 7: 17. It is a glycoprotein encoded on the short arm of chromosome 1 1. It was first isolated in hematopoietic cells and has since been found on a wide range of tissues, e.g., gastric, lung, liver and pancreas. The main ligands of CD44 are hyaluronan and osteopontin. The protein isoforms are encoded by a singe gene by alternative splicing and post-translational modification.
  • CD44 has numerous functions. It has been linked to cellular adhesion and CD44 positive cells have been identified as tumor initiating cells in gastric cancer. It also has a role in the immune system: lymphocyte homing and T-cell activation. Finally, high CD44 expression has been associated with poor prognosis in gastric adenocarcinoma. Ghaffarzadehgan et al. (2008) World J. Gastroenterol. 14(41):6376-6381. [0006] CD44 also has been identified as a gastric cancer stem cell marker. Takaishi et al. (2009) Stem Cells 27: 106-1020. CD44 gastric stem cells have reported properties of self- renewal, longevity and multipotency.
  • High CD44 protein expression correlates with the presence of dysplasia in murine and human gastric cancer.
  • CD44 overexpression has also been associated with chemo- and radio-resistance. Takaishi et al. (2009) Stem Cells 27: 106-1020 and Al-Hajj et al. (2003) PNAS 100:3983-3988.
  • rsl 871 16 (+4883G>A) and rs71 16432 (+779G>A) are independently and jointly associated with the clinical outcomes of patients with gastrointestinal cancer.
  • Gastrointestinal cancer patients harboring at least of the favorable genotypes (A/A for rsl 871 16 and G/G for rs71 16432) experience longer time to tumor recurrence as well as longer overall survival. These patients were treated with surgical resection, most of whom also received adjuvant 5-FU and/or radiation therapy.
  • the present disclosure provides methods for assessing the clinical outcome of gastrointestinal cancer patients. Those who harbor at least one of the favorable genotypes are predicted to experience longer time to tumor recurrence and/or overall survival and thus are suitable for the therapy. Conversely, those that do not show presence of either of the favorable genotypes are predicted to suffer shorter time to tumor recurrence and/or overall survival; hence for these patients more aggressive follow up examination and treatments may be needed.
  • one embodiment of the present disclosure provides a method for aiding in the identification of or identifying a gastrointestinal cancer patient as suitable or not suitable for a therapy comprising surgical resection, comprising screening or determining from a tissue or cell sample isolated from the patient the genotype of at least one polymorphism of CD44 RS I 871 16 or CD44 RS71 16432, wherein the presence of at least one genotype of (a) (A/ A) for CD44 rsl 871 16; or (b) (G/G) for CD44 rs71 16432 identifies the patient as suitable for the therapy, or the presence of neither of the genotypes identifies the patient as not suitable for the therapy.
  • the presence of at least one of the genotypes identifies the patient as suitable for the therapy.
  • the presence of neither of the genotypes identifies the patient as not suitable for the therapy.
  • Another embodiment provides a method for aiding in the determination of or determining whether a gastrointestinal cancer patient is likely to experience longer or shorter tumor recurrence following a therapy comprising surgical resection, comprising screening or determining from a tissue or cell sample isolated from the patient the genotype of at least one polymorphism of CD44 RS I 871 16 or CD44 RS71 16432, wherein the presence of at least one genotype of: (a) (A/A) for CD44 rs 1871 16; or (b) (G/G) for CD44 rs71 16432 determines that the patient is likely to experience longer tumor recurrence as compared to a patient having neither of the genotypes, or the presence of neither of the genotypes determines that the patient is likely to experience shorter tumor recurrence as compared to a patient having at least one of the genotypes.
  • the presence of at least one of the genotypes determines that the patient is likely to experience longer tumor recurrence as compared to a patient having neither of the genotypes. In another aspect, the presence of neither of the genotypes determines that the patient is likely to experience shorter tumor recurrence as compared to a patient having at least one of the genotypes.
  • FIG. 1 Another embodiment provides a method for aiding in the determination of or determining whether a gastrointestinal cancer patient is likely to experience longer or shorter overall survival following a therapy comprising surgical resection, comprising screening or determining from a tissue or cell sample isolated from the patient the genotype of at least one polymorphism of CD44 RS I 871 16 or CD44 RS71 16432, wherein the presence of at least one genotype of: (a) (A/A) for CD44 rs 1871 16; or (b) (G/G) for CD44 rs71 16432 determines that the patient is likely to experience longer overall survival as compared to a patient having neither of the genotypes, or the presence of neither of the genotypes determines that the patient is likely to experience shorter overall survival as compared to a patient having at least one of the genotypes.
  • the presence of at least one of the genotypes determines that the patient is likely to experience longer overall survival as compared to a patient having neither of the genotypes. In another aspect, the presence of neither of the genotypes determines that the patient is likely to experience shorter overall survival as compared to a patient having at least one of the genotypes.
  • the determination can be based upon the genotypes of both or either polymorphisms. Accordingly, the screening or determining of genotype can be done on both or either polymorphic sites.
  • another embodiment provides a method for aiding in the identification of or identifying a gastric cancer patient as suitable or not suitable for a therapy comprising surgical resection, comprising screening or determining from a tissue or cell sample isolated from the patient the genotype of polymorphisms of CD44
  • RS I 871 16 and CD44 RS71 16432 wherein the presence of genotypes of: (a) (A/A) for CD44 rsl 871 16; and (b) (G/G) for CD44 rs71 16432 identifies the patient as suitable for the therapy.
  • the gastrointestinal cancer patient suffers from gastric cancer, such as gastric adenocarcinoma.
  • gastric adenocarcinoma in some aspects, is localized gastric adenocarcinoma.
  • the therapy in one aspect, further comprises radiotherapy. In another aspect, the therapy further comprises chemotherapy.
  • the chemotherapy can be a 5-FU based chemotherapy that comprises the
  • 5-fluorouracil or a chemical equivalent thereof, or in combination with other chemotherapy commonly used together with 5-FU.
  • therapies include, without limitation, Leucovorin or "LV” (Folinic acid), a “platinum drug” such as oxaliplatin and cisplatin, and /or a topoisomerase inhibitor such as CPT-1 1.
  • This disclosure also provides methods for identifying and/or aiding in the identification of a gastrointestinal cancer patient as suitable or not suitable for a therapy comprising, or alternatively consisting essentially of, or yet further consisting of the administration of an effective amount of 5-fluorouracil or an equivalent thereof, comprising or alternatively consisting essentially of, or yet further consisting of determining a genotype of a cell or tissue sample isolated from the patient for the polymorphism CD44 rs 1871 16, wherein the presence of the genotype A/A identifies the patient as suitable for the therapy and the presence of the genotype A G or G/G identifies the patient as not suitable for the therapy.
  • the determination of the presence of the genotype A/A identifies the patient as suitable for the therapy. In another aspect, the determination of the presence of the genotype A G or G/G identifies the patient as not suitable for the therapy.
  • the gastrointestinal cancer is gastric cancer. In one aspect the gastric cancer is localized. In another aspect it is metastatic.
  • This disclosure also provides a method for identifying a gastrointestinal cancer patient as suitable or not suitable for a therapy comprising the administration of 5-fiuorouracil or an equivalent thereof, comprising or alternatively consisting essentially of, or yet further consisting of, determining a genotype of a cell or tissue sample isolated from the patient for the
  • the polymorphism CD44 rs71 16432 wherein the presence of the genotype G/G identifies the patient as suitable for the therapy and the presence of the genotype A G or A/A identifies the patient as not suitable for the therapy.
  • the genotype G/G identifies the patient as suitable for the therapy.
  • the genotype A/G or A/A identifies the patient as not suitable for the therapy.
  • the gastrointestinal cancer is gastric cancer which can be localized. In another aspect it is metastatic.
  • a method for identifying a patient having a gastrointestinal cancer suitable or not suitable for a therapy comprising or alternatively consisting of, or yet further consisting of the administration of 5-fluorouracil or an equivalent thereof, comprising or alternatively consisting essentially of, or yet further consisting of, determining a genotype of a cell or tissue sample isolated from the patient for the polymorphisms CD44 rsl 871 16 and CD44 rs71 16432, wherein the presence of at least one genotype of the group A/A for the polymorphism CD44 rsl 871 16 and G/G of the polymorphism CD44 rs71 16432 identifies the patient as suitable for the therapy and the absence of at least one of the group A/A for the polymorphism CD44 rsl 871 16 and G/G of the polymorphism CD44 rs71 16432 of the genotype A/G or G/G identifies the patient as not suitable for the therapy.
  • the presence of at least one genotype of the group A/A for the polymorphism CD44 rsl 871 16 and G/G of the polymorphism CD44 rs71 16432 identifies the patient as suitable for the therapy.
  • the presence of A/A for the polymorphism CD44 rsl 871 16 and G/G of the polymorphism CD44 rs71 16432 identifies the patient as suitable for the therapy.
  • the absence of at least one genotype of the group A/A for the polymorphism CD44 rsl 871 16 and G/G of the polymorphism CD rs71 16432 identifies the patient as not suitable for the therapy.
  • the gastrointestinal cancer is gastric cancer. In one aspect the gastric cancer is localized. In another aspect it is metastatic.
  • Also provided by this disclosure are methods for treating a gastrointestinal cancer patient selected for a therapy comprising, or alternatively consisting essentially of, or yet further consisting of the administration of an effective amount of 5-FU or an equivalent thereof, wherein the patient has been selected for the therapy by determining and identifying the presence of at least one genotype of CD44 rsl 871 16 (A/A) and CD44 rs71 16432 (G/G) in a cell or tissue sample isolated from the patient, thereby treating the gastrointestinal cancer patient.
  • the genotype is determined by screening a cell or tissue sample for the genotype by the methods provided herein.
  • the presence of the genotype CD44 rsl 871 16 identifies the patient as suitable for the therapy.
  • the genotype CD44 rs71 16432 identifies the patient as suitable for the therapy.
  • the genotype CD44 rs 1871 16 (A/A) and CD44 rs71 16432 (G/G) identifies the patient as suitable for the therapy. The absence of these genotypes indicates that the patient would not be effectively treated by the therapy and therefore the therapy should not be used.
  • the gastrointestinal cancer is gastric cancer. In one aspect the gastric cancer is localized. In another aspect it is metastatic.
  • the disclosure provides diagnostic methods for determining the polymorphic region of the gene of interest.
  • the methods use probes or primers comprising nucleotide sequences which are complementary to the gene of interest.
  • kits for performing these methods as well as instructions for carrying out the methods of this disclosure such as collecting tissue and/or performing the screen, and/or analyzing the results, and/or administration of an effective amount of a therapy as defined herein.
  • kits for performing these methods such as collecting tissue and/or performing the screen, and/or analyzing the results, and/or administration of an effective amount of a therapy as defined herein.
  • These can be used alone or in combination with other suitable therapy and/or radiation therapy.
  • kits for use in identifying a gastrointestinal cancer patient suitable for a therapy comprising, or alternatively consisting essentially of or yet further consisting of the administration of an effective amount of 5-FU or an equivalent thereof.
  • the kit comprises or alternatively consisting essentially of or yet further consists of suitable primers or probes for screening polymorphisms of CD44 rs71 16432 and/or CD44 rsl 871 16 of the CD44 gene, and instructions for use therein.
  • FIG. 1 through 6 graphically show the relative responsiveness of gastric cancer patients to the claimed therapies.
  • FIG. 1 graphically illustrates CD44 rsl 871 16 predicts tumor recurrence.
  • FIG. 2 graphically illustrates CD44 rsl 871 16 is associated with overall survival.
  • FIG. 3 graphically illustrates CD44 rsl 871 16 predicts tumor recurrence.
  • FIG. 4 graphically illustrates CD44 rsl 871 16 predicts overall survival.
  • FIG. 5 graphically illustrates combined analysis of risk alleles for time to recurrence.
  • FIG. 6 graphically illustrates combined analysis of risk alleles for overall survival.
  • PCR 1 A PRACTICAL APPROACH (M. MacPherson et al. IRL Press at Oxford University Press (1991)); PCR 2: A PRACTICAL APPROACH (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)); ANTIBODIES, A LABORATORY MANUAL (Harlow and Lane eds. (1999));
  • compositions and methods include the recited elements, but not excluding others.
  • Consisting essentially of when used to define compositions and methods shall mean excluding other elements of any essential significance to the composition or method.
  • Consisting of shall mean excluding more than trace elements of other ingredients for claimed compositions and substantial method steps.
  • compositions consisting of.
  • identify or “identifying” is to associate or affiliate a patient closely to a group or population of patients who likely experience the same or a similar clinical response to treatment.
  • alleles refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has two identical alleles of a gene, the subject is said to be homozygous for the gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene. Alleles of a specific gene can differ from each other in a single nucleotide, or several nucleotides, and can include substitutions, deletions and insertions of nucleotides. An allele of a gene can also be a form of a gene containing a mutation.
  • a polymorphic locus is a single nucleotide polymorphic
  • SNP locus If the allelic composition of a SNP locus is heterozygous, the genotype of the SNP locus will be identified as "X/Y" wherein X and Y are two different nucleotides, e.g., A G for the CD44 rs71 16432 SNP. If the allelic composition of a SNP locus is homozygous, the genotype of the SNP locus will be identified as "X X" wherein X identifies the nucleotide that is present at both alleles, e.g., G/G for CD44 rs71 16432.
  • a polymorphism can be expressed with a GenBank accession number, such as rsl 871 16 and rs71 16432.
  • polymorphisms can be referred to by its relative location and the common genotypes.
  • rsl 871 16 is also known as CD44 +4883G>A
  • rs71 16432 is also known as +779G>A.
  • genetic marker refers to an allelic variant of a polymorphic region of a gene of interest and/or the expression level of a gene of interest.
  • wild-type allele refers to an allele of a gene which, when present in two copies in a subject results in a wild-type phenotype. There can be several different wild-type alleles of a specific gene, since certain nucleotide changes in a gene may not affect the phenotype of a subject having two copies of the gene with the nucleotide changes.
  • polymorphism refers to the coexistence of more than one form of a gene or portion thereof.
  • a portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a "polymorphic region of a gene.”
  • polymorphic region can be a single nucleotide, the identity of which differs in different alleles.
  • a "polymorphic gene” refers to a gene having at least one polymorphic region.
  • the term “genotype” refers to the specific allelic composition of an entire cell or a certain gene and in some aspects a specific polymorphism associated with that gene, whereas the term “phenotype” refers to the detectable outward manifestations of a specific genotype.
  • amplification of polynucleotides includes methods such as PCR, ligation amplification (or ligase chain reaction, LCR) and amplification methods. These methods are known and widely practiced in the art. See, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202 and Innis et al, 1990 (for PCR); and Wu et al. (1989) Genomics 4:560-569 (for LCR).
  • the PCR procedure describes a method of gene amplification which is comprised of (i) sequence- specific hybridization of primers to specific genes within a DNA sample (or library), (ii) subsequent amplification involving multiple rounds of annealing, elongation, and denaturation using a DNA polymerase, and (iii) screening the PCR products for a band of the correct size.
  • the primers used are oligonucleotides of sufficient length and appropriate sequence to provide initiation of polymerization, i.e. each primer is specifically designed to be complementary to each strand of the genomic locus to be amplified.
  • Reagents and hardware for conducting PCR are commercially available.
  • Primers useful to amplify sequences from a particular gene region are preferably complementary to, and hybridize specifically to sequences in the target region or in its flanking regions.
  • Nucleic acid sequences generated by amplification may be sequenced directly. Alternatively the amplified sequence(s) may be cloned prior to sequence analysis.
  • a method for the direct cloning and sequence analysis of enzymatically amplified genomic segments is known in the art.
  • encode refers to a polynucleotide which is said to "encode” a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the mRNA for the polypeptide and/or a fragment thereof.
  • the antisense strand is the complement of such a nucleic acid, and the encoding sequence can be deduced therefrom.
  • the genetic marker or polymorphism is measured before and/or during treatment, and the values obtained are used by a clinician in assessing any of the following: (a) probable or likely suitability of an individual to initially receive treatment(s); (b) probable or likely unsuitability of an individual to initially receive treatment(s); (c) responsiveness to treatment; (d) probable or likely suitability of an individual to continue to receive treatment(s); (e) probable or likely unsuitability of an individual to continue to receive treatment(s); (f) adjusting dosage; (g) predicting likelihood of clinical benefits; or (h) toxicity.
  • information obtained using the diagnostic assays described herein may be used alone or in combination with other information, such as, but not limited to, genotypes or expression levels of other genes, clinical chemical parameters, histopathological parameters, or age, gender and weight of the subject.
  • the information obtained using the diagnostic assays described herein is useful in determining or identifying the clinical outcome of a treatment, selecting a patient for a treatment, or treating a patient, etc.
  • the information obtained using the diagnostic assays described herein is useful in aiding in the determination or identification of clinical outcome of a treatment, aiding in the selection of a patient for a treatment, or aiding in the treatment of a patient and etc.
  • the genotypes or expression levels of one or more genes as disclosed herein are used in a panel of genes, each of which contributes to the final diagnosis, prognosis or treatment.
  • the term "aiding” intends that the methods can be used in combination with other methods to select a therapy or to determine whether a gastrointestinal cancer patient is likely to experience longer or shorter tumor recurrence or longer or shorter overall survival.
  • a pathological parameter such as a T- or N-category
  • a T3 patient with an unfavorable genotype of CD44 determines that the patient is more likely to be at risk for tumor recurrence than a T2 patient having a favorable CD44 genotype.
  • the genotype of CD44 aids the determination based upon T-category characterization.
  • the term "treating" as used herein is intended to encompass curing as well as ameliorating at least one symptom of the condition or disease.
  • a response to treatment includes a reduction in cachexia, increase in survival time, elongation in time to tumor progression, reduction in tumor mass, reduction in tumor burden and/or a prolongation in time to tumor metastasis, an increase in time to tumor recurrence, tumor response, complete response, partial response, stable disease, progressive disease, progression free survival, an increase in overall survival, each as measured by standards set by the National Cancer Institute and the U.S. Food and Drug Administration for the approval of new drugs. See Johnson et al. (2003) J. Clin. Oncol. 21 (7): 1404-141 1.
  • An effective amount intends to indicated the amount of a compound or agent administered or delivered to the patient which is most likely to result in the desired response to treatment.
  • the amount is empirically determined by the patient's clinical parameters including, but not limited to the stage of disease, age, gender, histology, and likelihood for tumor recurrence.
  • clinical outcome refers to any clinical observation or measurement relating to a patient's reaction to a therapy.
  • clinical outcomes include tumor response (TR), overall survival (OS), progression free survival (PFS), disease free survival, time to tumor recurrence (TTR), time to tumor progression (TTP), relative risk (RR), toxicity or side effect.
  • the term "likely to respond” intends to mean that the patient of a genotype is relatively more likely to experience a complete response or partial response than a patient similarly situated without the genotype.
  • the term “not likely to respond” intends to mean that the patient of a genotype is relatively less likely to experience a complete response or partial response than a patient similarly situated without the genotype.
  • suitable for a therapy or “suitably treated with a therapy” shall mean that the patient is likely to exhibit one or more desirable clinical outcome as compared to a patient having the same disease and receiving the same therapy but possessing a different characteristic that is under consideration for the purpose of the comparison.
  • the characteristic under consideration is a genetic polymorphism or a somatic mutation.
  • the characteristic under consideration is expression level of a gene or a polypeptide.
  • a more desirable clinical outcome is relatively higher likelihood of or relatively overall survival, better tumor response such as tumor load reduction.
  • a more desirable clinical outcome is relatively longer overall survival.
  • a more desirable clinical outcome is relatively longer progression free survival or time to tumor progression.
  • a more desirable clinical outcome is relatively longer disease free survival.
  • a more desirable clinical outcome is relative reduction or delay in tumor recurrence.
  • a more desirable clinical outcome is relatively decreased metastasis.
  • a more desirable clinical outcome is relatively lower relative risk.
  • a more desirable clinical outcome is relatively reduced toxicity or side effects.
  • more than one clinical outcomes are considered simultaneously.
  • a patient possessing a characteristic such as a genotype of a genetic polymorphism, may exhibit more than one more desirable clinical outcome as compared to a patient having the same disease and receiving the same therapy but not possessing the characteristic. As defined herein, the patient is considered suitable for the therapy.
  • a patient possessing a characteristic may exhibit one or more desirable clinical outcome but simultaneously exhibit one or more less desirable clinical outcome.
  • the clinical outcomes will then be considered collectively, and a decision as to whether the patient is suitable for the therapy will be made accordingly, taking into account the patient's specific situation and the relevance of the clinical outcomes.
  • time to tumor recurrence and/or overall survival is weighted more heavily than others in a collective decision making.
  • a "complete response" (CR) to a therapy defines patients with evaluable but non- measurable disease, whose tumor and all evidence of disease had disappeared.
  • a "partial response" (PR) to a therapy defines patients with anything less than complete response that were simply categorized as demonstrating partial response.
  • SD stable disease
  • Progressive disease indicates that the tumor has grown (i.e. become larger), spread (i.e. metastasized to another tissue or organ) or the overall cancer has gotten worse following treatment. For example, tumor growth of more than 20 percent since the start of treatment typically indicates progressive disease.
  • Disease free survival indicates the length of time after treatment of a cancer or tumor during which a patient survives with no signs of the cancer or tumor.
  • Non-response (NR) to a therapy defines patients whose tumor or evidence of disease has remained constant or has progressed.
  • OS Global System for Mobile Communications
  • Progression free survival indicates the length of time during and after treatment that the cancer does not grow.
  • Progression-free survival includes the amount of time patients have experienced a complete response or a partial response, as well as the amount of time patients have experienced stable disease.
  • No Correlation refers to a statistical analysis showing no relationship between the allelic variant of a polymorphic region or gene expression levels and clinical parameters.
  • Tumor Recurrence as used herein and as defined by the National Cancer Institute is cancer that has recurred (come back), usually after a period of time during which the cancer could not be detected. The cancer may come back to the same place as the original (primary) tumor or to another place in the body. It is also called recurrent cancer.
  • TTR Time to Tumor Recurrence
  • Relative Risk in statistics and mathematical epidemiology, refers to the risk of an event (or of developing a disease) relative to exposure. Relative risk is a ratio of the probability of the event occurring in the exposed group versus a non-exposed group.
  • stomach cancer also called stomach cancer
  • adenocarcinomas which may be ulcerating, polypoid, diffuse, and fibrous, or superficial spreading lesions. Lymphomas and leiomyosarcomas account for less than 3%.
  • Symptoms of gastric cancer are vague epigastric discomfort, dysphagia, anorexia, weight loss, back pain, and unexplained iron deficiency anemia. However, many cases are asymptomatic in the early stages, and metastases may cause the first symptoms. Gastric cancer can spread to the liver, the pancreas, and other organs near the stomach as well as to the lungs.
  • Gastrointestinal cancer intends a cancer located or related to the gastrointestinal tract.
  • gastrointestinal cancer includes gastrointestinal stromal tumors (GIST), esophageal cancer, stomach cancer (gastric cancer), liver cancer, gallbladder cancer, pancreatic cancer, colorectal cancer including colon cancer, bowel cancer, and rectal cancer, and anal cancer.
  • Stage I cancer typically identifies that the primary tumor is limited to the organ of origin.
  • Stage II intends that the primary tumor has spread into surrounding tissue and lymph nodes immediately draining the area of the tumor.
  • Stage III intends that the primary tumor is large, with fixation to deeper structures.
  • Stage IV intends that the primary tumor is large, with fixation to deeper structures. See pages 20 and 21 , CANCER BIOLOGY, 2 nd Ed., Oxford University Press (1987).
  • a "tumor” is an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and serving no physiological function.
  • a “tumor” is also known as a neoplasm.
  • blood refers to blood which includes all components of blood circulating in a subject including, but not limited to, red blood cells, white blood cells, plasma, clotting factors, small proteins, platelets and/or cryoprecipitate. This is typically the type of blood which is donated when a human patent gives blood.
  • a "normal cell corresponding to the tumor tissue type” refers to a normal cell from a same tissue type as the tumor tissue.
  • a non-limiting examples is a normal lung cell from a patient having lung tumor, or a normal colon cell from a patient having colon tumor.
  • 5-Fluorouracil or "5-FU” is a pyrimidine analog, which is transformed into different cytotoxic metabolites that are then incorporated into DNA and RNA thereby inducing cell cycle arrest and apoptosis.
  • Chemical equivalents are pyrimidine analogs which result in disruption of DNA replication. Chemical equivalents inhibit cell cycle progression at S phase resulting in the disruption of cell cycle and consequently apoptosis.
  • 5-FU Equivalents to 5-FU include prodrugs, analogs and derivative thereof such as 5'-deoxy-5-fluorouridine (doxifluroidine), 1- tetrahydrofuranyl-5-fluorouracil (ftorafur), Capecitabine (Xeloda), S-l (MBMS-247616, consisting of tegafur and two modulators, a 5-chloro-2,4-dihydroxypyridine and potassium oxonate), ralititrexed (tomudex), nolatrexed (Thymitaq, AG337), LY231514 and ZD9331 , as described for example in Papamicheal (1999) The Oncologist 4:478-487.
  • pyrimidine antimetabolite drugs includes 5-FU based adjuvant therapy.
  • Capecitabine is a prodrug of (5-FU) that is converted to its active form by the tumor- specific enzyme PynPase following a pathway of three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR).
  • Capecitabine is marketed by Roche under the trade name Xeloda®.
  • Leucovorin or "LV" is an adjuvant used in cancer therapy. It is used in synergistic combination with 5-FU to improve efficacy of the chemo therapeutic agent. Without being bound by theory, addition of Leucovorin is believed to enhance efficacy of 5-FU by inhibiting thymidylate synthase. It has been used as an antidote to protect normal cells from high doses of the anticancer drug methotrexate and to increase the antitumor effects of fluorouracil (5- FU) and tegafur-uracil. It is also known as citrovoram factor and Wellcovorin.
  • This compound has the chemical designation of L-Glutamic acid N-[4-[[(2-amino-5-formyl- 1 ,4,5,6,7, 8- hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt (1 : 1).
  • a "platinum drag” intends a drag that contains platinum or is complexed to platinum for therapeutic efficacy.
  • Non-limiting examples include oxaliplatin, cisplatin, carboplatin, aroplatin, labaplatin, nedaplatin and JM-216.
  • Oxaliplatin (Eloxatin®) is a platinum-based chemotherapy drag in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Compared to cisplatin, the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility.
  • Oxaliplatin Equivalents to Oxaliplatin are known in the art and include, but are not limited to cisplatin, carboplatin, aroplatin, lobaplatin, nedaplatin, and JM-216 (see McKeage et al. (1997) J. Clin. Oncol. 201 : 1232-1237 and in general,
  • FOLFOX is an abbreviation for a type of combination therapy that is used to treat cancer. This therapy includes 5-FU, oxaliplatin and leucovorin. Information regarding these treatments are available on the National Cancer Institute's web site, cancer.gov, last accessed on January 16, 2008.
  • 5-FU based adjuvant therapy refers to 5-FU alone or alternatively the combination of 5-FU with other treatments, that include, but are not limited to radiation, methyl-CCNU, leucovorin, oxaliplatin, irinotecin, mitomycin, cytarabine, levamisole.
  • Specific treatment adjuvant regimens are known in the art as FOLFOX, FOLFOX4, FOLFIRI, MOF (semustine (methyl-CCNU), vincrisine (Oncovin) and 5-FU).
  • FOLFOX fluorous phosphate
  • FOLFOX4 irinotecin
  • MOF memustine (methyl-CCNU)
  • Oncovin Oncovin
  • 5-FU 5-FU
  • chemotherapeutics can be added, e.g., oxaliplatin or irinotecan.
  • Irinotecan (CPT-1 1) is sold under the trade name of Camptosar®. It is a semi-synthetic analogue of the alkaloid camptothecin, which is activated by hydrolysis to SN-38 and targets topoisomerase I. Chemical equivalents are those that inhibit the interaction of topoisomerase I and DNA to form a catalytically active topoisomerase I-DNA complex. Chemical equivalents inhibit cell cycle progression at G2-M phase resulting in the disruption of cell proliferation.
  • adjuvant cancer patient refers to a patient to which administration of a therapy or chemotherapeutic regimen has been given after removal of a tumor by surgery, usually termed adjuvant chemotherapy.
  • adjuvant therapy is typically given to minimize or prevent a possible cancer reoccurrence.
  • nonadjuvant therapy refers to administration of therapy or chemotherapeutic regimen before surgery, typically in an attempt to shrink the tumor prior to a surgical procedure to minimize the extent of tissue removed during the procedure.
  • first line or “second line” or “third line” refers to the order of treatment received by a patient.
  • First line therapy regimens are treatments given first, whereas second or third line therapy are given after the first line therapy or after the second line therapy, respectively.
  • the National Cancer Institute defines first line therapy as "the first treatment for a disease or condition.
  • primary treatment can be surgery, chemotherapy, radiation therapy, or a combination of these therapies.
  • First line therapy is also referred to those skilled in the art as "primary therapy and primary treatment.” See National Cancer Institute website as www.cancer.gov, last visited on May 1 , 2008.
  • a patient is given a subsequent chemotherapy regimen because the patient did not shown a positive clinical or subclinical response to the first line therapy or the first line therapy has stopped.
  • the term “equivalent” or “biological equivalent” of an antibody means the ability of the antibody to selectively bind its epitope protein or fragment thereof as measured by ELISA or other suitable methods.
  • Biologically equivalent antibodies include, but are not limited to, those antibodies, peptides, antibody fragments, antibody variant, antibody derivative and antibody mimetics that bind to the same epitope as the reference antibody.
  • the term “equivalent” of "chemical equivalent” of a chemical means the ability of the chemical to selectively interact with its target protein, DNA, RNA or fragment thereof as measured by the inactivation of the target protein, incorporation of the chemical into the DNA or RNA or other suitable methods.
  • Chemical equivalents include, but are not limited to, those agents with the same or similar biological activity and include, without limitation a pharmaceutically acceptable salt or mixtures thereof that interact with and/or inactivate the same target protein, DNA, or RNA as the reference chemical.
  • Cells "host cells” or “recombinant host cells” are terms used interchangeably herein.
  • isolated refers to molecules or biological or cellular materials being substantially free from other materials.
  • the term “isolated” refers to nucleic acid, such as DNA or RNA, or protein or polypeptide, or cell or cellular organelle, or tissue or organ, separated from other DNAs or RNAs, or proteins or polypeptides, or cells or cellular organelles, or tissues or organs, respectively, that are present in the natural source.
  • isolated also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
  • an "isolated nucleic acid” is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state.
  • isolated is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides.
  • isolated is also used herein to refer to cells or tissues that are isolated from other cells or tissues and is meant to encompass both cultured and engineered cells or tissues.
  • a "native” or “natural” or “wild-type” antigen is a polypeptide, protein or a fragment which contains an epitope and which has been isolated from a natural biological source. It also can specifically bind to an antigen receptor.
  • an “antibody” includes whole antibodies and any antigen binding fragment or a single chain thereof.
  • the term “antibody” includes any protein or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule. Examples of such include, but are not limited to a complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework (FR) region, or any portion thereof, or at least one portion of a binding protein, any of which can be incorporated into an antibody of the present invention.
  • CDR complementarity determining region
  • an antibody is used in combination with the above-noted chemotherapy or for diagnosis or as an alternative to the chemotherapy, the antibodies can be polyclonal or monoclonal and can be isolated from any suitable biological source, e.g., murine, rat, sheep and canine. Additional sources are identified infra.
  • the term "antibody” is further intended to encompass digestion fragments, specified portions, derivatives and variants thereof, including antibody mimetics or comprising portions of antibodies that mimic the structure and/or function of an antibody or specified fragment or portion thereof, including single chain antibodies and fragments thereof.
  • binding fragments encompassed within the term "antigen binding portion" of an antibody include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH, domains; a F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH, domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, a dAb fragment (Ward et al. (1989) Nature 341 :544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR).
  • Fab fragment a monovalent fragment consisting of the VL, VH, CL and CH, domains
  • F(ab') 2 fragment a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region
  • a Fd fragment consisting of the VH and CH, domains
  • the two domains of the Fv fragment, VL and VH are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv)).
  • scFv single chain Fv
  • Single chain antibodies are also intended to be encompassed within the term "fragment of an antibody.” Any of the above-noted antibody fragments are obtained using conventional techniques known to those of skill in the art, and the fragments are screened for binding specificity and neutralization activity in the same manner as are intact antibodies.
  • epitope means a protein determinant capable of specific binding to an antibody.
  • Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.
  • antibody variant is intended to include antibodies produced in a species other than a mouse. It also includes antibodies containing post-translational modifications to the linear polypeptide sequence of the antibody or fragment. It further encompasses fully human antibodies.
  • antibody derivative is intended to encompass molecules that bind an epitope as defined above and which are modifications or derivatives of a native monoclonal antibody of this invention. Derivatives include, but are not limited to, for example, bispecific, multispecific, heterospecific, trispecific, tetraspecific, multispecific antibodies, diabodies, chimeric, recombinant and humanized.
  • bispecific molecule is intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has two different binding specificities.
  • agent e.g., a protein, peptide, or protein or peptide complex
  • multispecific molecule or “heterospecific molecule” is intended to include any agent, e.g. a protein, peptide, or protein or peptide complex, which has more than two different binding specificities.
  • heteroantibodies refers to two or more antibodies, antibody binding fragments (e.g., Fab), derivatives thereof, or antigen binding regions linked together, at least two of which have different specificities.
  • human antibody as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
  • the human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • human antibody as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • human antibody refers to an antibody in which substantially every part of the protein (e.g., CDR, framework, C L , C H domains (e.g., C HI , C H2 , Cm), hinge, (VL, VH)) is substantially non-immunogenic in humans, with only minor sequence changes or variations.
  • antibodies designated primate monkey, baboon, chimpanzee, etc.
  • rodent mouse, rat, rabbit, guinea pig, hamster, and the like
  • other mammals designate such species, sub-genus, genus, sub-family, family specific antibodies.
  • chimeric antibodies include any combination of the above.
  • a human antibody is distinct from a chimeric or humanized antibody. It is pointed out that a human antibody can be produced by a non-human animal or prokaryotic or eukaryotic cell that is capable of expressing functionally rearranged human immunoglobulin (e.g., heavy chain and/or light chain) genes. Further, when a human antibody is a single chain antibody, it can comprise a linker peptide that is not found in native human antibodies.
  • an Fv can comprise a linker peptide, such as two to about eight glycine or other amino acid residues, which connects the variable region of the heavy chain and the variable region of the light chain.
  • linker peptides are considered to be of human origin.
  • a human antibody is "derived from” a particular germline sequence if the antibody is obtained from a system using human immunoglobulin sequences, e.g., by immunizing a transgenic mouse carrying human immunoglobulin genes or by screening a human immunoglobulin gene library.
  • a human antibody that is "derived from” a human germline immunoglobulin sequence can be identified as such by comparing the amino acid sequence of the human antibody to the amino acid sequence of human germline immunoglobulins.
  • a selected human antibody typically is at least 90% identical in amino acids sequence to an amino acid sequence encoded by a human germline immunoglobulin gene and contains amino acid residues that identify the human antibody as being human when compared to the germline immunoglobulin amino acid sequences of other species (e.g., murine germline sequences).
  • a human antibody may be at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino acid sequence encoded by the germline immunoglobulin gene.
  • a human antibody derived from a particular human germline sequence will display no more than 10 amino acid differences from the amino acid sequence encoded by the human germline immunoglobulin gene.
  • the human antibody may display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the amino acid sequence encoded by the germline immunoglobulin gene.
  • monoclonal antibody or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition.
  • a monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.
  • a "human monoclonal antibody” refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline
  • recombinant human antibody includes all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom, antibodies isolated from a host cell transformed to express the antibody, e.g., from a transfectoma, antibodies isolated from a recombinant, combinatorial human antibody library, and antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences.
  • Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences.
  • such recombinant human antibodies can be subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • isotype refers to the antibody class (e.g., IgM or IgGl) that is encoded by heavy chain constant region genes.
  • the disclosure further provides diagnostic, prognostic and therapeutic methods, which are based, at least in part, on determination of the identity of the polymorphic region of the CD44 gene.
  • the disclosure provides a method for identifying and/or aiding in the identification of a gastrointestinal cancer such a gastric cancer patient as suitable or not suitable for a therapy comprising, or alternatively consisting essentially of, or yet further consisting of the administration of an effective amount of 5-fluorouracil or an equivalent thereof, comprising or alternatively consisting essentially of, or yet further consisting of determining a genotype of a cell or tissue sample isolated from the patient for the polymorphism CD44 rs 1871 16, wherein the presence of the genotype A/A identifies the patient as suitable for the therapy and the presence of the genotype A/G or G/G identifies the patient as not suitable for the therapy.
  • the method comprises, or alternatively consists essentially of, or yet further consists of, the determination of the presence of the genotype A/A as identifying the patient as suitable for the therapy.
  • method comprises, or alternatively consists essentially of, or yet further consists of, the determination of the presence of the genotype A/G or G/G as identifying the patient as not suitable for the therapy.
  • Another aspect of the disclosure is a method for identifying or aiding in the
  • identification of a gastrointestinal cancer such a gastric cancer patient as suitable or not suitable for a therapy comprising, or alternatively consists essentially of, or yet further consists of, the administration of 5-fluorouracil or an equivalent thereof, comprising or alternatively consisting essentially of, or yet further consisting of determining a genotype of a cell or tissue sample isolated from the patient for the polymorphism CD44 rs71 16432, wherein the presence genotype G/G identifies the patient as suitable for the therapy and the presence of the genotype A/G or A/A identifies the patient as not suitable for the therapy.
  • the determination of the presence of the genotype G/G identifies the patient as suitable for the therapy.
  • the determination of the presence of the genotype A/G or A/A identifies the patient as not suitable for the therapy.
  • a method for identifying a patient having a gastrointestinal cancer such a gastric cancer as suitable or not suitable for a therapy comprising or alternatively consisting essentially of, or yet further consisting of the administration of 5-fluorouracil or an equivalent thereof, comprising or alternatively consisting essentially of, or yet further consisting of determining a genotype of a cell or tissue sample isolated from the patient for the
  • polymorphism CD44 rsl 871 16 and CD44 rs71 16432 wherein the presence of one or both genotype(s) of the group A/A for the polymorphism CD44 rsl 871 16 and G/G of the
  • polymorphism CD44 rs71 16432 identifies the patient as suitable for the therapy and the absence of at least one of the group A/A for the polymorphism CD44 rsl 871 16 and G/G of the polymorphism CD44 rs71 16432 of the genotype A/G or G/G identifies the patient as not suitable for the therapy.
  • the determination of the presence of at least one or both genotype of the group A/A for the polymorphism CD44 rsl 871 16 and G/G of the polymorphism CD44 rs71 16432 identifies the patient as suitable for the therapy.
  • the absence of at least one genotype of the group A/A for the polymorphism CD44 rs 1871 16 and G/G of the polymorphism CD rs71 16432 identifies the patient as not suitable for the therapy.
  • the gastric cancer in one aspect is localized. In another aspect it is metastatic gastric cancer.
  • a patient of a genotype that is suitable for the therapy is a patient that has relatively longer time to tumor recurrence than a patient not having the genotype and having the cancer and receiving the therapy.
  • a patient of a genotype that is suitable for the therapy is a patient that has relatively longer overall survival time than a patient not having the genotype and having the cancer and receiving the therapy.
  • a patient of a genotype that is suitable for the therapy is a patient that has relatively longer time to tumor recurrence and relatively longer overall survival that a patient not having the genotype and having the cancer and receiving the therapy.
  • the gastric cancer patient has localized gastric cancer.
  • the gastric cancer patient has localized gastric cancer and the therapy is administered subsequent to tumor removal (resection).
  • the patient has metastatic gastric cancer and the therapy is administered as 1 st line, 2 nd line or 3 rd line therapy.
  • the therapies that are considered for the methods of this disclosure include a therapy comprising, consisting essentially of or yet further consisting of 5-FU or an equivalent thereof, 5- FU adjuvant therapy, 5-FU or an equivalent thereof in combination with leucovorin (LV), 5-FU or an equivalent thereof in combination with LV and a platinum drug or 5-FU or an equivalent thereof in combination with a platinum drug and a topoisomerase inhibitor.
  • a therapy comprising, consisting essentially of or yet further consisting of 5-FU or an equivalent thereof, 5- FU adjuvant therapy, 5-FU or an equivalent thereof in combination with leucovorin (LV), 5-FU or an equivalent thereof in combination with LV and a platinum drug or 5-FU or an equivalent thereof in combination with a platinum drug and a topoisomerase inhibitor.
  • LV leucovorin
  • 5-FU or an equivalent thereof in combination with LV a platinum drug or 5-FU or an equivalent thereof in combination with a platinum drug and a topoisomerase inhibitor.
  • the therapy further comprises, or alternatively consists
  • the cell or tissue sample comprises or alternatively consists essentially of or yet further consists of, at least one of a tumor cell, a normal cell adjacent to a tumor, a normal cell distal to the tumor, a normal cell corresponding to the tumor tissue type, a blood cell, a peripheral blood lymphocyte, or combinations thereof.
  • the cell or tissue sample comprises or alternatively consists essentially of or yet further consists of, a peripheral blood lymphocyte.
  • the samples to be screened can be any sample that would provide a genotypic analysis. Not limiting examples include at least one of a fixed tissue, a frozen tissue, a biopsy tissue, a resection tissue, a microdissected tissue, or combinations thereof.
  • any suitable method for determining the genotype of the sample can be used in the practice of these methods.
  • such methods comprise, or alternatively consist essentially of, or yet further consist of, PCR, PCR-RFLP, sequencing, or micro array.
  • the methods are useful in the diagnosis, prognosis and treatment of patients.
  • patients include but are not limited to animals, such as mammals which can include simians, ovines, bovines, murines, canines, felines, equines, and humans.
  • information obtained using the diagnostic assays described herein is useful for determining if a subject will likely, more likely, or less likely to respond to cancer treatment of a given type. Based on the prognostic information, a doctor can recommend a therapeutic protocol, useful for treating reducing the malignant mass or tumor in the patient or treat cancer in the individual.
  • knowledge of the identity of a particular allele in an individual allows customization of therapy for a particular disease to the individual's genetic profile, the goal of "pharmacogenomics".
  • an individual's genetic profile can enable a doctor: 1) to more effectively prescribe a drug that will address the molecular basis of the disease or condition; 2) to better determine the appropriate dosage of a particular drug and 3) to identify novel targets for drug development.
  • the identity of the genotype or expression patterns of individual patients can then be compared to the genotype or expression profile of the disease to determine the appropriate drug and dose to administer to the patient.
  • Detection of point mutations or additional base pair repeats can be accomplished by molecular cloning of the specified allele and subsequent sequencing of that allele using techniques known in the art, in some aspects, after isolation of a suitable nucleic acid sample using methods known in the art.
  • the gene sequences can be amplified directly from a genomic DNA preparation from the tumor tissue using PCR, and the sequence composition is determined from the amplified product.
  • numerous methods are available for isolating and analyzing a subject's DNA for mutations at a given genetic locus such as the gene of interest.
  • a detection method is allele specific hybridization using probes overlapping the polymorphic site and having about 5, or alternatively 10, or alternatively 20, or alternatively 25, or alternatively 30 nucleotides around the polymorphic region.
  • several probes capable of hybridizing specifically to the allelic variant are attached to a solid phase support, e.g., a "chip".
  • Oligonucleotides can be bound to a solid support by a variety of processes, including lithography. For example a chip can hold up to 250,000 oligonucleotides (GeneChip, Affymetrix). Mutation detection analysis using these chips comprising oligonucleotides, also termed "DNA probe arrays" is described e.g., in Cronin et al. (1996) Human Mutation 7:244.
  • Amplification can be performed, e.g., by PCR and/or LCR, according to methods known in the art.
  • genomic DNA of a cell is exposed to two PCR primers and amplification for a number of cycles sufficient to produce the required amount of amplified DNA.
  • Alternative amplification methods include: self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86: 1 173-1 177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6: 1 197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques known to those of skill in the art. These detection schemes are useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
  • any of a variety of sequencing reactions known in the art can be used to directly sequence at least a portion of the gene of interest and detect allelic variants, e.g., mutations, by comparing the sequence of the sample sequence with the corresponding wild-type (control) sequence.
  • Exemplary sequencing reactions include those based on techniques developed by Maxam and Gilbert (1997) Proc. Natl. Acad. Sci. USA 74:560) or Sanger et al. (1977) Proc. Nat. Acad. Sci. 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the subject assays (Biotechniques (1995) 19:448), including sequencing by mass spectrometry (see, for example, U.S. Patent No.
  • the occurrence of only one, two or three of the nucleic acid bases need be determined in the sequencing reaction.
  • A-track or the like e.g., where only one nucleotide is detected, can be carried out.
  • Yet other sequencing methods are disclosed, e.g., in U.S. Patent No. 5,580,732 entitled “Method of DNA Sequencing Employing A Mixed DNA-Polymer Chain Probe” and U.S. Patent No. 5,571 ,676 entitled “Method For Mismatch-Directed In Vitro DNA Sequencing.”
  • the presence of the specific allele in DNA from a subject can be shown by restriction enzyme analysis.
  • the specific nucleotide polymorphism can result in a nucleotide sequence comprising a restriction site which is absent from the nucleotide sequence of another allelic variant.
  • protection from cleavage agents can be used to detect mismatched bases in RNA RNA DNA DNA, or RNA/DNA heteroduplexes (see, e.g., Myers et al. (1985) Science 230: 1242).
  • the technique of "mismatch cleavage” starts by providing heteroduplexes formed by hybridizing a control nucleic acid, which is optionally labeled, e.g., RNA or DNA, comprising a nucleotide sequence of the allelic variant of the gene of interest with a sample nucleic acid, e.g., RNA or DNA, obtained from a tissue sample.
  • a control nucleic acid which is optionally labeled, e.g., RNA or DNA
  • sample nucleic acid e.g., RNA or DNA
  • RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S I nuclease to enzymatically digest the mismatched regions.
  • either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine whether the control and sample nucleic acids have an identical nucleotide sequence or in which nucleotides they are different. See, for example, U.S. Patent No. 6,455,249, Cotton et al. (1988) Proc. Natl. Acad. Sci. USA 85:4397; Saleeba et al. (1992) Methods Enzy. 217:286-295.
  • the control or sample nucleic acid is labeled for detection.
  • alterations in electrophoretic mobility is used to identify the particular allelic variant.
  • SSCP single strand conformation polymorphism
  • Single-stranded DNA fragments of sample and control nucleic acids are denatured and allowed to renature.
  • the secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change.
  • the DNA fragments may be labeled or detected with labeled probes.
  • the sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence.
  • the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet. 7:5).
  • the identity of the allelic variant is obtained by analyzing the movement of a nucleic acid comprising the polymorphic region in polyacrylamide gels containing a gradient of denaturant, which is assayed using denaturing gradient gel
  • DGGE electrophoresis
  • Examples of techniques for detecting differences of at least one nucleotide between 2 nucleic acids include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension.
  • oligonucleotide probes may be prepared in which the known polymorphic nucleotide is placed centrally (allele-specific probes) and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324: 163); Saiki et al. (1989) Proc. Natl. Acad. Sci. USA 86:6230 and Wallace et al. (1979) Nucl. Acids Res. 6:3543).
  • oligonucleotide hybridization techniques may be used for the detection of the nucleotide changes in the polymorphic region of the gene of interest.
  • oligonucleotides having the nucleotide sequence of the specific allelic variant are attached to a hybridizing membrane and this membrane is then hybridized with labeled sample nucleic acid.
  • hybridization signal will then reveal the identity of the nucleotides of the sample nucleic acid.
  • allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant disclosure.
  • Oligonucleotides used as primers for specific amplification may carry the allelic variant of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 1 1 :238 and Newton et al. (1989) Nucl. Acids Res.
  • identification of the allelic variant is carried out using an oligonucleotide ligation assay (OLA), as described, e.g., in U.S. Patent No. 4,998,617 and in Landegren et al. (1988) Science 241 : 1077-1080.
  • OLA oligonucleotide ligation assay
  • the OLA protocol uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target.
  • One of the oligonucleotides is linked to a separation marker, e.g., biotinylated, and the other is detectably labeled.
  • oligonucleotides will hybridize such that their termini abut, and create a ligation substrate. Ligation then permits the labeled oligonucleotide to be recovered using avidin, or another biotin ligand.
  • Nickerson et al. have described a nucleic acid detection assay that combines attributes of PCR and OLA (Nickerson et al. (1990) Proc. Natl. Acad. Sci. (U.S.A.) 87:8923-8927). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.
  • each OLA reaction can be detected by using hapten specific antibodies that are labeled with different enzyme reporters, alkaline phosphatase or horseradish peroxidase.
  • This system permits the detection of the two alleles using a high throughput format that leads to the production of two different colors.
  • the single base polymorphism can be detected by using a specialized exonuclease-resistant nucleotide, as disclosed, e.g., in Mundy, C. R. (U.S. Patent No. 4,656,127).
  • a primer complementary to the allelic sequence immediately 3 ' to the polymorphic site is permitted to hybridize to a target molecule obtained from a particular animal or human. If the polymorphic site on the target molecule contains a nucleotide that is complementary to the particular exonuclease-resistant nucleotide derivative present, then that derivative will be incorporated onto the end of the hybridized primer.
  • a solution-based method is used for determining the identity of the nucleotide of the polymorphic site.
  • Cohen et al. (French Patent 2,650,840; PCT Appln. No. WO91/02087).
  • a primer is employed that is complementary to allelic sequences immediately 3' to a polymorphic site.
  • the method determines the identity of the nucleotide of that site using labeled dideoxynucleotide derivatives, which, if complementary to the nucleotide of the polymorphic site will become incorporated onto the terminus of the primer.
  • GBA Genetic Bit Analysis
  • Goelet et al. PCT Appln. No. 92/15712
  • This method uses mixtures of labeled terminators and a primer that is complementary to the sequence 3' to a polymorphic site.
  • the labeled terminator that is incorporated is thus determined by, and complementary to, the nucleotide present in the polymorphic site of the target molecule being evaluated.
  • the method of Goelet et al. supra is preferably a heterogeneous phase assay, in which the primer or the target molecule is immobilized to a solid phase.
  • the polymorphic region is located in the coding region of the gene of interest, yet other methods than those described above can be used for determining the identity of the allelic variant. For example, identification of the allelic variant, which encodes a mutated signal peptide, can be performed by using an antibody specifically recognizing the mutant protein in, e.g., immunohisto chemistry or immunoprecipitation. Antibodies to the wild-type or signal peptide mutated forms of the signal peptide proteins can be prepared according to methods known in the art.
  • a solid phase support is used as a support capable of binding of a primer, probe, polynucleotide, an antigen or an antibody.
  • Well-known supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.
  • the nature of the support can be either soluble to some extent or insoluble for the purposes of the present disclosure.
  • the support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody.
  • the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
  • the surface may be flat such as a sheet, test strip, etc. or alternatively polystyrene beads.
  • suitable supports for binding antibody or antigen or will be able to ascertain the same by use of routine experimentation.
  • any of the above methods for detecting alterations in a gene or gene product or polymorphic variants can be used to monitor the course of treatment or therapy.
  • the methods described herein may be performed, for example, by utilizing prepackaged diagnostic kits, such as those described below, comprising at least one probe or primer nucleic acid described herein, which may be conveniently used, e.g. , to determine whether a subject is likely to experience tumor recurrence or longer overall survival following therapy as described herein.
  • Sample nucleic acid for use in the above-described diagnostic and prognostic methods can be obtained from any suitable cell type or tissue of a subject.
  • a subject's bodily fluid e.g. blood
  • nucleic acid tests can be performed on dry samples (e.g., hair or skin). Diagnostic procedures can also be performed in situ directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary.
  • Nucleic acid reagents can be used as probes and/or primers for such in situ procedures (see, for example, Nuovo (1992) PCR IN SITU HYBRIDIZATION: PROTOCOLS AND APPLICATIONS, Raven Press, NY).
  • Fingerprint profiles can be generated, for example, by utilizing a differential display procedure, Northern analysis and/or RT-PCR.
  • Antibodies directed against wild type or mutant peptides encoded by the allelic variants of the gene of interest may also be used in disease diagnostics and prognostics. Such diagnostic methods, may be used to detect abnormalities in the level of expression of the peptide, or abnormalities in the structure and/or tissue, cellular, or subcellular location of the peptide.
  • Protein from the tissue or cell type to be analyzed may easily be detected or isolated using techniques which are well known to one of skill in the art, including but not limited to Western blot analysis.
  • Western blot analysis For a detailed explanation of methods for carrying out Western blot analysis, see Sambrook and Russell (2001) supra.
  • the protein detection and isolation methods employed herein can also be such as those described in Harlow and Lane (1999) supra. This can be accomplished, for example, by immunofluorescence techniques employing a fiuorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorimetric detection.
  • the antibodies (or fragments thereof) useful in the present disclosure may, additionally, be employed histologically, as in immunofluorescence or immunoelectron microscopy, for in situ detection of the peptides or their allelic variants.
  • In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody of the present disclosure.
  • the antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample.
  • Amplification can be performed, e.g., by PCR and/or LCR, according to methods known in the art.
  • PCR e.g., by PCR and/or LCR, according to methods known in the art.
  • Various non-limiting examples of PCR include the herein described methods.
  • Allele-specific PCR is a diagnostic or cloning technique is used to identify or utilize single-nucleotide polymorphisms (SNPs). It requires prior knowledge of a DNA sequence, including differences between alleles, and uses primers whose 3' ends encompass the SNP. PCR amplification under stringent conditions is much less efficient in the presence of a mismatch between template and primer, so successful amplification with an SNP-specific primer signals presence of the specific SNP in a sequence (See, Saiki et al. (1986) Nature 324(6093): 163-166 and U.S. Patent Nos.: 5,821 ,062; 7,052,845 or 7,250,258).
  • Assembly PCR or Polymerase Cycling Assembly is the artificial synthesis of long DNA sequences by performing PCR on a pool of long oligonucleotides with short overlapping segments.
  • the oligonucleotides alternate between sense and antisense directions, and the overlapping segments determine the order of the PCR fragments thereby selectively producing the final long DNA product (See, Stemmer et al. (1995) Gene 164(l):49-53 and U.S. Patent Nos.: 6,335, 160; 7,058,504 or 7,323,336)
  • Asymmetric PCR is used to preferentially amplify one strand of the original DNA more than the other. It finds use in some types of sequencing and hybridization probing where having only one of the two complementary stands is required. PCR is carried out as usual, but with a great excess of the primers for the chosen strand. Due to the slow amplification later in the reaction after the limiting primer has been used up, extra cycles of PCR are required (See, Innis et al. (1988) Proc Natl Acad Sci U.S.A. 85(24):9436-9440 and U.S.
  • Colony PCR uses bacterial colonies, for example E. coli, which can be rapidly screened by PCR for correct DNA vector constructs. Selected bacterial colonies are picked with a sterile toothpick and dabbed into the PCR master mix or sterile water. The PCR is started with an extended time at 95 °C when standard polymerase is used or with a shortened denaturation step at 100°C and special chimeric DNA polymerase (Pavlov et al. (2006) "Thermostable DNA
  • Helicase-dependent amplification is similar to traditional PCR, but uses a constant temperature rather than cycling through denaturation and annealing/extension cycles.
  • DNA Helicase an enzyme that unwinds DNA, is used in place of thermal denaturation (See, Myriam et al. (2004) EMBO reports 5(8):795-800 and U.S. Patent No. 7,282,328).
  • Hot-start PCR is a technique that reduces non-specific amplification during the initial set up stages of the PCR.
  • the technique may be performed manually by heating the reaction components to the melting temperature (e.g., 95°C) before adding the polymerase (Chou et al. (1992) Nucleic Acids Research 20: 1717-1723 and U.S. Patent Nos.: 5,576,197 and 6,265,169).
  • Specialized enzyme systems have been developed that inhibit the polymerase's activity at ambient temperature, either by the binding of an antibody (Sharkey et al. (1994) Bio/Technology 12:506-509) or by the presence of covalently bound inhibitors that only dissociate after a high- temperature activation step.
  • Hot-start/cold- finish PCR is achieved with new hybrid polymerases that are inactive at ambient temperature and are instantly activated at elongation temperature.
  • ISSR Intersequence-specific PCR method for DNA fingerprinting that amplifies regions between some simple sequence repeats to produce a unique fingerprint of amplified fragment lengths
  • Inverse PCR is a method used to allow PCR when only one internal sequence is known. This is especially useful in identifying flanking sequences to various genomic inserts. This involves a series of DNA digestions and self ligation, resulting in known sequences at either end of the unknown sequence (Ochman et al. (1988) Genetics 120:621-623 and U.S. Patent Nos.: 6,013,486; 6,106,843 or 7, 132,587).
  • Ligation-mediated PCR uses small DNA linkers ligated to the DNA of interest and multiple primers annealing to the DNA linkers; it has been used for DNA sequencing, genome walking, and DNA footprinting (Mueller et al. (1988) Science 246:780-786).
  • Methylation-specific PCR is used to detect methylation of CpG islands in genomic DNA (Herman et al. (1996) Proc Natl Acad Sci U.S.A. 93(13):9821 -9826 and U.S. Patent Nos.: 6,81 1 ,982; 6,835,541 or 7,125,673). DNA is first treated with sodium bisulfite, which converts unmethylated cytosine bases to uracil, which is recognized by PCR primers as thymine. Two PCRs are then carried out on the modified DNA, using primer sets identical except at any CpG islands within the primer sequences.
  • MLPA Multiplex Ligation-dependent Probe Amplification
  • Nested PCR increases the specificity of DNA amplification, by reducing background due to non-specific amplification of DNA.
  • Two sets of primers are being used in two successive PCRs. In the first reaction, one pair of primers is used to generate DNA products, which besides the intended target, may still consist of non-specifically amplified DNA fragments.
  • the product(s) are then used in a second PCR with a set of primers whose binding sites are completely or partially different from and located 3' of each of the primers used in the first reaction (See, U.S. Patent Nos.: 5,994,006; 7,262,030 or 7,329,493).
  • Nested PCR is often more successful in specifically amplifying long DNA fragments than conventional PCR, but it requires more detailed knowledge of the target sequences.
  • Overlap-extension PCR is a genetic engineering technique allowing the construction of a DNA sequence with an alteration inserted beyond the limit of the longest practical primer length.
  • Quantitative PCR also known as RQ-PCR, QRT-PCR and RTQ-PCR, is used to measure the quantity of a PCR product following the reaction or in real-time. See, U.S. Patent
  • Q-PCR is the method of choice to quantitatively measure starting amounts of DNA, cDNA or RNA.
  • Q-PCR is commonly used to determine whether a DNA sequence is present in a sample and the number of its copies in the sample. The method with currently the highest level of accuracy is digital PCR as described in U.S. Patent
  • RT-PCR refers to reverse transcription PCR (see below), which is often used in conjunction with Q-PCR.
  • QRT-PCR methods use fluorescent dyes, such as Sybr Green, or fiuorophore-containing DNA probes, such as TaqMan, to measure the amount of amplified product in real time.
  • RT-PCR Reverse Transcription PCR
  • RACE-PCR Rapid Amplification of cDNA Ends
  • TAIL-PCR Thermal asymmetric interlaced PCR
  • PCR Touchdown PCR a variant of PCR that aims to reduce nonspecific background by gradually lowering the annealing temperature as PCR cycling progresses.
  • the annealing temperature at the initial cycles is usually a few degrees (3-5°C) above the T m of the primers used, while at the later cycles, it is a few degrees (3-5 °C) below the primer T m .
  • the higher temperatures give greater specificity for primer binding, and the lower temperatures permit more efficient amplification from the specific products formed during the initial cycles (Don et al. (1991) Nucl. Acids Res. 19:4008 and U.S. Patent No. 6,232,063).
  • probes are labeled with two fluorescent dye molecules to form so-called “molecular beacons” (Tyagi and Kramer (1996) Nat. Biotechnol.
  • molecular beacons signal binding to a complementary nucleic acid sequence through relief of intramolecular fluorescence quenching between dyes bound to opposing ends on an oligonucleotide probe.
  • the use of molecular beacons for genotyping has been described (Kostrikis (1998) Science 279: 1228-9) as has the use of multiple beacons simultaneously (Marras (1999) Genet. Anal. 14: 151 -6).
  • a quenching molecule is useful with a particular fluorophore if it has sufficient spectral overlap to substantially inhibit fluorescence of the fluorophore when the two are held proximal to one another, such as in a molecular beacon, or when attached to the ends of an oligonucleotide probe from about 1 to about 25 nucleotides.
  • Labeled probes also can be used in conjunction with amplification of a gene of interest.
  • U.S. Patent No. 5,210,015 by Gelfand et al. describe fluorescence-based approaches to provide real time measurements of amplification products during PCR.
  • Such approaches have either employed intercalating dyes (such as ethidium bromide) to indicate the amount of double-stranded DNA present, or they have employed probes containing fluorescence-quencher pairs (also referred to as the "Taq-Man" approach) where the probe is cleaved during amplification to release a fluorescent molecule whose concentration is proportional to the amount of double-stranded DNA present.
  • the probe is digested by the nuclease activity of a polymerase when hybridized to the target sequence to cause the fluorescent molecule to be separated from the quencher molecule, thereby causing fluorescence from the reporter molecule to appear.
  • the Taq-Man approach uses a probe containing a reporter molecule—quencher molecule pair that specifically anneals to a region of a target polynucleotide containing the polymorphism.
  • Probes can be affixed to surfaces for use as "gene chips.” Such gene chips can be used to detect genetic variations by a number of techniques known to one of skill in the art. In one technique, oligonucleotides are arrayed on a gene chip for determining the DNA sequence of a by the sequencing by hybridization approach, such as that outlined in U.S. Patent Nos. 6,025,136 and 6,018,041. The probes of the disclosure also can be used for fluorescent detection of a genetic sequence. Such techniques have been described, for example, in U.S. Patent Nos.
  • a probe also can be affixed to an electrode surface for the
  • This disclosure also provides for a prognostic panel of genetic markers selected from, but not limited to the genetic polymorphisms identified herein.
  • the prognostic panel comprises probes or primers that can be used to amplify and/or for determining the molecular structure of the polymorphisms identified herein.
  • the probes or primers can be attached or supported by a solid phase support such as, but not limited to a gene chip or microarray.
  • the probes or primers can be detectably labeled.
  • This aspect of the disclosure is a means to identify the genotype of a patient sample for the genes of interest identified above.
  • the panel of probes and/or primers will identify a genotype of a cell or tissue sample for at least one or more of CD44 rsl 871 16 and CD44 rs71 16432 a CD44 gene.
  • the panel contains the herein identified probes or primers as wells as other probes or primers.
  • the panel includes one or more of the above noted probes or primers and others.
  • the panel consist only of the above-noted probes or primers.
  • Primers or probes can be affixed to surfaces for use as "gene chips” or "microarray.” Such gene chips or microarrays can be used to detect genetic variations by a number of techniques known to one of skill in the art. In one technique, oligonucleotides are arrayed on a gene chip for determining the DNA sequence by the sequencing by hybridization approach, such as that outlined in U.S. Patent Nos. 6,025,136 and 6,018,041. The probes of the disclosure also can be used for fluorescent detection of a genetic sequence. Such techniques have been described, for example, in U.S. Patent Nos. 5,968,740 and 5,858,659.
  • a probe also can be affixed to an electrode surface for the electrochemical detection of nucleic acid sequences such as described by Kayem et al. U.S. Patent No. 5,952, 172 and by Kelley et al. (1999) Nucleic Acids Res. 27:4830-4837.
  • GeneChip (Affymetric, Inc); LabChip (Caliper Technologies Corp); a low-density array with electrochemical sensing (Clinical Micro Sensors); LabCD System (Gamera Bioscience Corp.); Omni Grid (Gene Machines); Q Array (Genetix Ltd.); a high-throughput, automated mass spectrometry systems with liquid-phase expression technology (Gene Trace Systems, Inc.); a thermal jet spotting system (Hewlett Packard Company); Hyseq HyChip (Hyseq, Inc.);
  • BeadArray (Illumina, Inc.); GEM (Incyte Microarray Systems); a high-throughput microarraying system that can dispense from 12 to 64 spots onto multiple glass slides (Intelligent Bio- Instruments); Molecular Biology Workstation and anoChip ( anogen, Inc.); a micro fluidic glass chip (Orchid biosciences, Inc.); BioChip Arrayer with four PiezoTip piezoelectric drop-on- demand tips (Packard Instruments, Inc.); FlexJet (Rosetta Inpharmatic, Inc.); MALDI-TOF mass spectrometer (Sequnome); ChipMaker 2 and ChipMaker 3 (TeleChem International, Inc.); and GenoSensor (Vysis, Inc.) as identified and described in Heller (2002) Annu.
  • probes or primers for the gene of interest are provided alone or in combination with other probes and/or primers.
  • a suitable sample is obtained from the patient extraction of genomic DNA, R A, or any combination thereof and amplified if necessary.
  • the DNA or RNA sample is contacted to the gene chip or microarray panel under conditions suitable for hybridization of the gene(s) of interest to the probe(s) or primer(s) contained on the gene chip or microarray.
  • the probes or primers may be detectably labeled thereby identifying the polymorphism in the gene(s) of interest.
  • a chemical or biological reaction may be used to identify the probes or primers which hybridized with the DNA or RNA of the gene(s) of interest.
  • the genetic profile of the patient is then determined with the aid of the aforementioned apparatus and methods.
  • the nucleic acid sequences of the gene of interest, or portions thereof can be the basis for probes or primers, e.g., in methods for determining the allelic variant of a polymorphic region of a gene of interest identified in the experimental section below. Thus, they can be used in the methods of the disclosure to determine which therapy is most likely to treat an individual's cancer.
  • the methods of the disclosure can use nucleic acids isolated from vertebrates.
  • the vertebrate nucleic acids are mammalian nucleic acids.
  • the nucleic acids used in the methods of the disclosure are human nucleic acids.
  • Primers for use in the methods of the disclosure are nucleic acids which hybridize to a nucleic acid sequence which is adjacent to the region of interest or which covers the region of interest and is extended. A primer can be used alone in a detection method, or a primer can be used together with at least one other primer or probe in a detection method. Primers can also be used to amplify at least a portion of a nucleic acid.
  • Probes for use in the methods of the disclosure are nucleic acids which hybridize to the gene of interest and which are not further extended.
  • a probe is a nucleic acid which hybridizes to the gene of interest, and which by hybridization or absence of hybridization to the DNA of a subject will be indicative of the identity of the allelic variant of the expression levels of the gene of interest.
  • Primers and/or probes for use in the methods can be provided as isolated single stranded oligonucleotides or alternatively, as isolated double stranded oligonucleotides.
  • primers comprise a nucleotide sequence which comprises a region having a nucleotide sequence which hybridizes under stringent conditions to about: 6, or alternatively 8, or alternatively 10, or alternatively 12, or alternatively 25, or alternatively 30, or alternatively 40, or alternatively 50, or alternatively 75 consecutive nucleotides of the gene of interest at the polymorphic region of interest CD44 rs71 16432 and/or CD44 rs 1871 16.
  • Primers can be complementary to nucleotide sequences located close to each other or further apart, depending on the use of the amplified DNA.
  • primers can be chosen such that they amplify DNA fragments of at least about 10 nucleotides or as much as several kilobases.
  • the primers of the disclosure will hybridize selectively to nucleotide sequences located about 100 to about 1000 nucleotides apart.
  • a forward primer i.e., 5' primer
  • a reverse primer i.e., 3' primer
  • Forward and reverse primers hybridize to complementary strands of a double stranded nucleic acid, such that upon extension from each primer, a double stranded nucleic acid is amplified.
  • primers of the disclosure are nucleic acids which are capable of selectively hybridizing to the polymorphic region of the gene of interest.
  • primers can be specific for the gene of interest sequence, so long as they have a nucleotide sequence which is capable of hybridizing to the gene of interest.
  • the probe or primer may further comprises a label attached thereto, which, e.g., is capable of being detected, e.g. the label group is selected from amongst radioisotopes, fluorescent compounds, enzymes, and enzyme co-factors.
  • nucleic acids used as probes or primers may be modified to become more stable.
  • exemplary nucleic acid molecules which are modified include
  • nucleic acids used in the methods of the disclosure can also be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule.
  • the nucleic acids, e.g., probes or primers may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane. See, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. 84:648-652; and PCT Publ. No. WO 88/09810, published Dec. 15, 1988), hybridization-triggered cleavage agents, (see, e.g., Krol et al. (1988)
  • nucleic acid used in the methods of the disclosure may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
  • the isolated nucleic acids used in the methods of the disclosure can also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose or, alternatively, comprise at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a
  • phosphorodithioate a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.
  • nucleic acids, or fragments thereof, to be used in the methods of the disclosure can be prepared according to methods known in the art and described, e.g., in Sambrook et al. (2001) supra.
  • discrete fragments of the DNA can be prepared and cloned using restriction enzymes.
  • discrete fragments can be prepared using the Polymerase Chain Reaction (PCR) using primers having an appropriate sequence under the manufacturer's conditions, (described above).
  • Oligonucleotides can be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.).
  • an automated DNA synthesizer such as are commercially available from Biosearch, Applied Biosystems, etc.
  • phosphorothioate oligonucleotides can be synthesized by the method of Stein et al. (1988) Nucl. Acids Res. 16:3209
  • methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports. Sarin et al. (1988) Proc. Natl. Acad. Sci. USA 85:7448-7451.
  • the disclosure further provides methods for treating gastrointestinal cancer such a gastric cancer patients identified as being suitable for the treatment.
  • the methods for identifying these patients are identified herein.
  • a patient is suitable if he or she is more likely to respond to the therapy than another patient receiving the same therapy and having the same cancer but not identified or determined to be suitable for the therapy.
  • a patient is suitable for the therapy if he experiences a relatively longer time to tumor recurrence than a patient having the same cancer and receiving the same therapy but not identified or determined to be suitable for the therapy.
  • a patient is suitable for the therapy if he experiences a relatively overall survival time than a patient having the same cancer and receiving the same therapy but not identified or determined to be suitable for the therapy.
  • the gastric cancer patient has localized gastric cancer.
  • the gastric cancer patient has localized gastric cancer and the therapy is administered subsequent to tumor removal (resection).
  • the patient has metastatic gastric cancer and the therapy is administered as 1 st line, 2 nd line or 3 rd line therapy.
  • the therapies that are considered for the methods of this disclosure include a therapy comprising, consisting essentially of or yet further consisting administration of an effective amount of 5-FU or an equivalent thereof, 5-FU adjuvant therapy, 5-FU or an equivalent thereof in combination with leucovorin (LV), 5-FU or an equivalent thereof in combination with LV and a platinum drug or 5-FU or an equivalent thereof in combination with a platinum drug and a topoisomerase inhibitor.
  • a therapy comprising, consisting essentially of or yet further consisting administration of an effective amount of 5-FU or an equivalent thereof, 5-FU adjuvant therapy, 5-FU or an equivalent thereof in combination with leucovorin (LV), 5-FU or an equivalent thereof in combination with LV and a platinum drug or 5-FU or an equivalent thereof in combination with a platinum drug and a topoisomerase inhibitor.
  • LV leucovorin
  • a platinum drug or 5-FU or an equivalent thereof in combination with a platinum drug and a topoisomerase inhibitor is CPT-1 1 or an equivalent thereof.
  • the therapy further comprises, or alternatively consists essentially of, or yet further consists of, the administration of an effective amount of radiation therapy.
  • the genotype of a cell or tissue sample isolated from the patient is determined by assaying any suitable cell or tissue that comprises, or alternatively consists essentially of, or yet further consists of, at least one of a tumor cell, a normal cell adjacent to a tumor, a normal cell distal to the tumor, a normal cell corresponding to the tumor tissue type, a blood cell, a peripheral blood lymphocyte, or combinations thereof, which can be in a form of at least one of a fixed tissue, a frozen tissue, a biopsy tissue, a resection tissue, a microdissected tissue, or combinations thereof.
  • any suitable method for determining the genotype of the sample can be used in the practice of these methods.
  • such methods comprise, or alternatively consist essentially of, or yet further consist of, PCR, PCR-RFLP, sequencing, or micro array.
  • the methods are useful to treat patients that include but are not limited to animals, such as mammals which can include simians, ovines, bovines, murines, canines, equines, and humans.
  • animals such as mammals which can include simians, ovines, bovines, murines, canines, equines, and humans.
  • this disclosure provides the method for treating a gastrointestinal cancer such a gastric cancer patient selected for a therapy comprising the administration of an effective amount of 5-FU or an equivalent thereof, wherein the patient has been selected for the therapy by determining the presence of at least one genotype of CD44 rsl 871 16 (A/ A) and CD44 rs71 16432 (G/G) in a cell or tissue sample isolated from the patient, thereby treating the cancer patient.
  • the genotype is determined by screening a cell or tissue sample for the genotype by the methods provided above.
  • the presence of the genotype CD44 rsl 871 16 (A/ A) identifies the patient as suitable for the therapy.
  • the genotype CD44 rs71 16432 (G/G) identifies the patient as suitable for the therapy.
  • the genotype CD44 rsl 871 16 (A A) and CD44 rs71 16432 (G/G) identifies the patient as suitable for the therapy. The absence of at least one of these genotypes indicates that the patient would not be effectively treated by the therapy.
  • chemotherapeutic agents or drugs can be administered as a composition.
  • composition typically intends a combination of the active agent and another carrier, e.g., compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant, diluent, binder, stabilizer, buffers, salts, lipophilic solvents, preservative, adjuvant or the like and include pharmaceutically acceptable carriers.
  • carrier e.g., compound or composition
  • inert for example, a detectable agent or label
  • active such as an adjuvant, diluent, binder, stabilizer, buffers, salts, lipophilic solvents, preservative, adjuvant or the like and include pharmaceutically acceptable carriers.
  • Carriers also include pharmaceutical excipients and additives proteins, peptides, amino acids, lipids, and carbohydrates (e.g., sugars, including monosaccharides, di-, tri-, tetra-, and oligosaccharides; derivatized sugars such as alditols, aldonic acids, esterified sugars and the like; and polysaccharides or sugar polymers), which can be present singly or in combination, comprising alone or in combination 1-99.99% by weight or volume.
  • Exemplary protein excipients include serum albumin such as human serum albumin (HSA), recombinant human albumin (rHA), gelatin, casein, and the like.
  • amino acid/antibody components which can also function in a buffering capacity, include alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, and the like.
  • Carbohydrate excipients are also intended within the scope of this disclosure, examples of which include but are not limited to monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol sorbitol (glucitol) and
  • the term carrier further includes a buffer or a pH adjusting agent; typically, the buffer is a salt prepared from an organic acid or base.
  • Representative buffers include organic acid salts such as salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris, tromethamine hydrochloride, or phosphate buffers.
  • Additional carriers include polymeric excipients/additives such as polyvinylpyrrolidones, ficolls (a polymeric sugar), dextrates (e.g., cyclodextrins, such as 2 -hydroxypropyl-. quadrature. - cyclodextrin), polyethylene glycols, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, surfactants (e.g., polysorbates such as "TWEEN 20" and
  • TWEEN 80 lipids (e.g., phospholipids, fatty acids), steroids (e.g., cholesterol), and chelating agents (e.g., EDTA).
  • lipids e.g., phospholipids, fatty acids
  • steroids e.g., cholesterol
  • chelating agents e.g., EDTA
  • the term "pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
  • the compositions also can include stabilizers and preservatives and any of the above noted carriers with the additional proviso that they be acceptable for use in vivo.
  • stabilizers and adjuvants see Martin REMINGTON'S PHARM. SCI., 15th Ed. (Mack Publ. Co., Easton (1975) and Williams & Williams, (1995), and in the "PHYSICIAN'S DESK
  • chemotherapies and molecular targeted therapies, biologic therapies, and radiation therapies are also well known to the art; including therapies such as trastuzumab plus paclitaxel, alone or in further combination with platinum compounds such as oxaliplatin, for certain breast cancers, and many other such regimens for other cancers; and the "Dublin regimen” 5-fluorouracil IV over 16 hours on days 1- 5 and 75 mg/m 2 cisplatin IV or oxaliplatin over 8 hours on day 7, with repetition at 6 weeks, in combination with 40 Gy radiotherapy in 15 fractions over the first 3 weeks) and the "Michigan regimen” (fluorouracil plus cisplatin or oxaliplatin plus vinblastine plus radiotherapy), both for esophageal cancer, and many other such regimens for other cancers, including colorectal cancer.
  • therapies such as trastuzumab plus paclitaxel, alone or in further combination with platinum compounds such as oxaliplatin, for certain breast cancers, and many other such
  • the method for treating a patient further comprises, or alternatively consists essentially of, or yet further consists of surgical resection of a metastatic or non-metastatic solid malignant tumor and, in some aspects, in combination with radiation.
  • Methods for treating these tumors as Stage I, Stage II, Stage III, or Stage IV by surgical resection and/or radiation are known to one skilled in the art. Guidelines describing methods for treatment by surgical resection and/or radiation can be found at the National Comprehensive Cancer Network's web site, nccn.org, last accessed on May 27, 2008.
  • the chemotherapy is delivered after surgical resection of localized gastric cancer.
  • the therapy is administered to a metastatic gastric cancer patient as a 1 st line, 2 nd line or 3 rd line therapy.
  • the disclosure provides an article of manufacture, comprising packaging material and at least one vial comprising a solution of the therapy as described herein with the prescribed buffers and/or preservatives, optionally in an aqueous diluent, wherein said packaging material comprises a label that indicates that such solution can be held over a period of 1 , 2, 3, 4, 5, 6, 9, 12, 18, 20, 24, 30, 36,40, 48, 54, 60, 66, 72 hours or greater.
  • agents identified herein as effective for their intended purpose can be administered to subjects or individuals identified by the methods herein as suitable for the therapy.
  • Therapeutic amounts can be empirically determined and will vary with the pathology being treated, the subject being treated and the efficacy and toxicity of the agent.
  • a medicament comprising an effective amount of a therapeutic as described herein for treatment of a human cancer patient having the polymorphism of the gene of interest as identified in the experimental examples.
  • compositions are well known to those of ordinary skill in the art and include, but are not limited to, oral, microinjection, intravenous or parenteral administration.
  • the compositions are intended for topical, oral, or local
  • Administration as well as intravenously, subcutaneously, or intramuscularly. Administration can be effected continuously or intermittently throughout the course of the treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the cancer being treated and the patient, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
  • the disclosure provides diagnostic methods for determining the polymorphic region of the gene of interest.
  • the methods use probes or primers comprising nucleotide sequences which are complementary to the gene of interest.
  • the disclosure provides kits for performing these methods as well as instructions for carrying out the methods of this disclosure such as collecting tissue and/or performing the screen, and/or analyzing the results, and/or administration of an effective amount of a therapy as defined herein. These can be used alone or in combination with other suitable chemotherapy or biological therapy and/or radiation therapy.
  • kit for use in identifying a gastrointestinal cancer such a gastric cancer patient suitable for a therapy comprising, or alternatively consisting essentially of or yet further consisting of the administration of an effective amount of 5-FU or an equivalent thereof, comprising or alternatively consisting essentially of or yet further consisting of suitable primers or probes for screening polymorphisms of CD44 rs71 16432 and/or CD44 rs 1871 16 of the CD44 gene, and instructions for use therein.
  • the kit further comprises or alternatively consists essentially or yet further consists of a therapy comprising or alternatively consisting essentially of or yet further consisting of the administration of 5-FU adjuvant therapy or 5-FU or an equivalent thereof and optionally instructions for use of the therapy to treat the cancer patient.
  • the therapy is selected from the group of 5-FU, 5-FU adjuvant therapy, 5-FU or an equivalent thereof and leucovorin (LV), 5-FU or an equivalent thereof and LV and a platinum drug or 5-FU or an equivalent thereof and a plantinum drug and a topoisomerase inhibitor.
  • the therapy comprises or alternatively consists essentially of or yet further consists of 5-FU adjuvant therapy or 5-FU or an equivalent thereof and LV.
  • the therapy comprises or alternatively consists essentially or yet further consists of 5-FU or an equivalent thereof and LV and a platinum drug.
  • the therapy comprises or alternatively consists essentially or yet further consists of 5-FU or an equivalent thereof and a platinum drug and a topoisomerase inhibitor. Examples of these therapies are provided above, e.g., wherein the platinum drug is cisplatin or oxaliplatin or an equivalent thereof and the topoisomerase inhibitor is CPT-1 1 or an equivalent thereof.
  • the kit may further contain instructions for the administration of radiation therapy to the patient in combination with the above-noted therapies.
  • the kit can also contain instructions for screening a patient sample to determine the genotype when the sample is selected from at least one of a tumor cell, a normal cell adjacent to a tumor, a normal cell distal to the tumor, a normal cell corresponding to the tumor tissue type, a blood cell, peripheral blood lymphocyte, or combinations thereof.
  • the instructions for use comprise instructions for screening a patient sample selected from at least one of a fixed tissue, a frozen tissue, a biopsy tissue, a resection tissue, a microdissected tissue, or combinations thereof and/or instructions for screening by a method comprising PCR, PCR-RFLP, sequencing, or microarray.
  • the test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are known in the art and can be readily adapted in order to obtain a sample which is compatible with the system utilized.
  • kits for determining response to cancer treatment containing a first and a second oligonucleotide specific for the polymorphic region of the gene. Examples of such are provided herein.
  • Oligonucleotides "specific for" the gene of interest bind either to the gene of interest or bind adjacent to the gene of interest.
  • primers are adjacent if they are sufficiently close to be used to produce a polynucleotide comprising the gene of interest.
  • oligonucleotides are adjacent if they bind within about 1-2 kb, and preferably less than 1 kb from the gene of interest. Specific oligonucleotides are capable of hybridizing to a sequence, and under suitable conditions will not bind to a sequence differing by a single nucleotide.
  • kits are useful to screen and treat patients that include but are not limited to animals, such as mammals which can include simians, ovines, bovines, murines, canines, equines, and humans.
  • the kit can comprise at least one probe or primer which is capable of specifically hybridizing to the gene of interest and instructions for use.
  • the kits preferably comprise at least one of the above described nucleic acids.
  • Preferred kits for amplifying at least a portion of the gene of interest comprise two primers, at least one of which is capable of hybridizing to the allelic variant sequence.
  • Such kits are suitable for detection of genotype by, for example, fluorescence detection, by electrochemical detection, or by other detection.
  • Oligonucleotides whether used as probes or primers, contained in a kit can be detectably labeled. Labels can be detected either directly, for example for fluorescent labels, or indirectly. Indirect detection can include any detection method known to one of skill in the art, including biotin-avidin interactions, antibody binding and the like. Fluorescently labeled oligonucleotides also can contain a quenching molecule. Oligonucleotides can be bound to a surface. In one embodiment, the preferred surface is silica or glass. In another embodiment, the surface is a metal electrode.
  • kits of the disclosure comprise at least one reagent necessary to perform the assay.
  • the kit can comprise an enzyme.
  • the kit can comprise a buffer or any other necessary reagent.
  • Conditions for incubating a nucleic acid primer with a test sample depend on the format employed in the assay, the detection methods used, and the type and nature of the nucleic acid primer used in the assay.
  • One skilled in the art will recognize that any one of the commonly available hybridization, amplification or immunological assay formats can readily be adapted to employ the nucleic acid probes for use in the present disclosure. Examples of such assays can be found in Chard (1986) AN INTRODUCTION TO RADIOIMMUNOASSAY AND RELATED TECHNIQUES Elsevier Science Publishers, Amsterdam, The Netherlands; Bullock et al., TECHNIQUES IN IMMUNOCYTOCHEMISTRY Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen (1985) PRACTICE AND THEORY OF
  • kits can include all or some of the positive controls, negative controls, reagents, primers, sequencing markers, probes and antibodies described herein for determining the subject's genotype in the polymorphic region of the gene of interest.
  • these suggested kit components may be packaged in a manner customary for use by those of skill in the art.
  • these suggested kit components may be provided in solution or as a liquid dispersion or the like.
  • the identification of the polymorphic region or the expression level of the gene of interest can also be useful for identifying an individual among other individuals from the same species.
  • DNA sequences can be used as a fingerprint for detection of different individuals within the same species. Thompson and Thompson, eds., (1991) GENETICS IN MEDICINE, W B Saunders Co., Philadelphia, Pa. This is useful, e.g., in forensic studies.
  • CD44 is a transmembrane glycoprotein serving as receptor of hyaluronan and osteopontin, is associated with adhesion and metastasis in gastrointestinal carcinomas.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a pour objet des méthodes diagnostiques et thérapeutiques pour aider à identifier un patient atteint d'un cancer gastro-intestinal qui présentera une réponse thérapeutique positive au traitement comprenant l'administration de 5-fluoro-uracile ou de son équivalent, comparé à des patients dans une situation similaire. La méthode comprend la détermination d'un génotype d'une cellule ou d'un échantillon de tissu isolé à partir du patient pour des polymorphismes sélectionnés dans le gène CD44.
PCT/US2011/020718 2010-01-11 2011-01-10 Polymorphismes du cd44 prédisant le résultat clinique chez des patients atteints d'un cancer gastrique WO2011085334A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29404010P 2010-01-11 2010-01-11
US61/294,040 2010-01-11

Publications (1)

Publication Number Publication Date
WO2011085334A1 true WO2011085334A1 (fr) 2011-07-14

Family

ID=43899654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020718 WO2011085334A1 (fr) 2010-01-11 2011-01-10 Polymorphismes du cd44 prédisant le résultat clinique chez des patients atteints d'un cancer gastrique

Country Status (1)

Country Link
WO (1) WO2011085334A1 (fr)

Citations (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656127A (en) 1983-04-22 1987-04-07 Amersham International Plc. Method of detecting mutations in DNA and RNA
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1988009810A1 (fr) 1987-06-11 1988-12-15 Synthetic Genetics Nouveaux conjugues d'acide nucleique amphiphile
FR2650840A1 (fr) 1989-08-11 1991-02-15 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
WO1992015712A1 (fr) 1991-03-05 1992-09-17 Molecular Tool, Inc. Determination d'acides nucleiques par extension de la polymerase d'oligonucleotides a l'aide de melanges terminateurs
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1994016101A2 (fr) 1993-01-07 1994-07-21 Koester Hubert Sequençage d'adn par spectrometrie de masse
WO1994021822A1 (fr) 1993-03-19 1994-09-29 Sequenom, Inc. Sequençage de l'adn au moyen de la spectrometrie de masse par degradation a l'exonuclease
US5571676A (en) 1995-06-07 1996-11-05 Ig Laboratories, Inc. Method for mismatch-directed in vitro DNA sequencing
US5576197A (en) 1995-04-07 1996-11-19 Molecular Bio-Products Polymerase chain reaction container and methods of using the same
US5576180A (en) 1995-05-01 1996-11-19 Centre De Recherche De L'hopital Ste-Justine Primers and methods for simultaneous amplification of multiple markers for DNA fingerprinting
US5580732A (en) 1992-04-03 1996-12-03 The Perkin Elmer Corporation Method of DNA sequencing employing a mixed DNA-polymer chain probe
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5821062A (en) 1994-03-29 1998-10-13 Sumitomo Chemical Company, Limited Oligonucleotide for use in checking presence or absence of mutation in human-derived cytochrome P450IIC18 gene
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5882856A (en) 1995-06-07 1999-03-16 Genzyme Corporation Universal primer sequence for multiplex DNA amplification
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5994006A (en) 1996-06-04 1999-11-30 Nikon Corporation Projection exposure methods
US6013486A (en) 1997-09-17 2000-01-11 Yale University Method for selection of insertion mutants
US6018041A (en) 1987-04-01 2000-01-25 Hyseq, Inc. Method of sequencing genomes by hybridization of oligonucleotide probes
US6025136A (en) 1994-12-09 2000-02-15 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US6106843A (en) 1996-12-10 2000-08-22 Council Of Scientific & Industrial Research Process for the isolation of a nontoxinogenic vibrio cholerae strain and a process for preparing cholera vaccine from said vibrio cholerae strain
US6106777A (en) 1994-11-09 2000-08-22 Hitachi, Ltd. DNA analyzing method and device therefor
US6232063B1 (en) 1995-08-07 2001-05-15 Association Francaise Contre Les Myopathies Co-dominant genetic diagnosis test
US6258540B1 (en) 1997-03-04 2001-07-10 Isis Innovation Limited Non-invasive prenatal diagnosis
US6265169B1 (en) 1997-05-22 2001-07-24 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Method based on the use of bacteriophages for the detection biological molecules in biological samples
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6440705B1 (en) 1998-10-01 2002-08-27 Vincent P. Stanton, Jr. Method for analyzing polynucleotides
US6455249B1 (en) 1997-09-10 2002-09-24 National Institutes Of Health Method of amplifying DNA and RNA mismatch cleavage products
US6531282B1 (en) 2000-05-30 2003-03-11 Oligotrail, Llc Multiplex amplification and analysis of selected STR loci
US6759195B1 (en) 1999-03-25 2004-07-06 University Of Maryland Biotechnology Institute Method of differential display of prokaryotic messenger RNA by RTPCR
US6811982B2 (en) 1997-06-09 2004-11-02 University Of Southern California Cancer diagnostic method based upon DNA methylation differences
US6835541B2 (en) 2001-01-26 2004-12-28 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
US7052845B2 (en) 1996-04-04 2006-05-30 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US7058504B2 (en) 2002-11-26 2006-06-06 Navteq North America, Llc Method for organizing map data
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US7101663B2 (en) 2001-03-02 2006-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education PCR method
US7118867B2 (en) 2001-11-20 2006-10-10 Roche Diagnostics Corporation Quantitative multiplex PCR with high dynamic range
US7125673B2 (en) 2002-03-25 2006-10-24 Chun-Yang Fan CpG retrieval of DNA from formalin-fixed pathology specimen for promoter methylation analysis
US7132587B2 (en) 2001-11-08 2006-11-07 Agency Of Industrial Science And Technology Non-autonomous transposon gene of rice, transformed plant and method of use
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US7179600B2 (en) 2001-04-12 2007-02-20 Biocore Co., Ltd. Oligonucleotide chip composition and a method for analyzing a hepatitis C virus genotype using the composition
US20070048749A1 (en) * 2005-08-30 2007-03-01 Chiung-Nien Chen Method for survival prediction in gastric cancer patients after surgical operation using gene expression profiles and application thereof
US7188030B2 (en) 2001-08-21 2007-03-06 Applera Corporation Automatic threshold setting for quantitative polymerase chain reaction
US20070059765A1 (en) 2005-03-22 2007-03-15 Denong Wang Liposome-based microarray and methods of use thereof
US20070059769A1 (en) 2004-03-05 2007-03-15 Ola Blixt High throughput glycan microarrays
US20070084997A1 (en) 2004-06-11 2007-04-19 Ngk Insulators, Ltd. Method of producing microarray
US20070099198A1 (en) 2005-03-14 2007-05-03 California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
US7250258B2 (en) 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
US7262030B2 (en) 2001-05-09 2007-08-28 Virginia Commonwealth University Multiple sequencible and ligatible structures for genomic analysis
US20070202525A1 (en) 2006-02-02 2007-08-30 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
US7282328B2 (en) 2002-09-20 2007-10-16 New England Biolabs, Inc. Helicase dependent amplification of nucleic acids
US7317111B2 (en) 2002-09-23 2008-01-08 Aries Associates, Inc. Green and orange fluorescent labels and their uses
US7323336B2 (en) 2001-02-21 2008-01-29 Verenium Corporation Enzymes having alpha amylase activity and methods of use thereof
US7329493B2 (en) 2004-12-22 2008-02-12 Asiagen Corporation One-tube nested PCR for detecting Mycobacterium tuberculosis
US9603651B2 (en) 2013-02-21 2017-03-28 Medtronic, Inc. Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms

Patent Citations (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656127A (en) 1983-04-22 1987-04-07 Amersham International Plc. Method of detecting mutations in DNA and RNA
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683195B1 (fr) 1986-01-30 1990-11-27 Cetus Corp
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US6018041A (en) 1987-04-01 2000-01-25 Hyseq, Inc. Method of sequencing genomes by hybridization of oligonucleotide probes
WO1988009810A1 (fr) 1987-06-11 1988-12-15 Synthetic Genetics Nouveaux conjugues d'acide nucleique amphiphile
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840A1 (fr) 1989-08-11 1991-02-15 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
WO1991002087A1 (fr) 1989-08-11 1991-02-21 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1992015712A1 (fr) 1991-03-05 1992-09-17 Molecular Tool, Inc. Determination d'acides nucleiques par extension de la polymerase d'oligonucleotides a l'aide de melanges terminateurs
US5580732A (en) 1992-04-03 1996-12-03 The Perkin Elmer Corporation Method of DNA sequencing employing a mixed DNA-polymer chain probe
WO1994016101A2 (fr) 1993-01-07 1994-07-21 Koester Hubert Sequençage d'adn par spectrometrie de masse
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
WO1994021822A1 (fr) 1993-03-19 1994-09-29 Sequenom, Inc. Sequençage de l'adn au moyen de la spectrometrie de masse par degradation a l'exonuclease
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5821062A (en) 1994-03-29 1998-10-13 Sumitomo Chemical Company, Limited Oligonucleotide for use in checking presence or absence of mutation in human-derived cytochrome P450IIC18 gene
US6106777A (en) 1994-11-09 2000-08-22 Hitachi, Ltd. DNA analyzing method and device therefor
US6025136A (en) 1994-12-09 2000-02-15 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5576197A (en) 1995-04-07 1996-11-19 Molecular Bio-Products Polymerase chain reaction container and methods of using the same
US5576180A (en) 1995-05-01 1996-11-19 Centre De Recherche De L'hopital Ste-Justine Primers and methods for simultaneous amplification of multiple markers for DNA fingerprinting
US5882856A (en) 1995-06-07 1999-03-16 Genzyme Corporation Universal primer sequence for multiplex DNA amplification
US5571676A (en) 1995-06-07 1996-11-05 Ig Laboratories, Inc. Method for mismatch-directed in vitro DNA sequencing
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US6232063B1 (en) 1995-08-07 2001-05-15 Association Francaise Contre Les Myopathies Co-dominant genetic diagnosis test
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US7052845B2 (en) 1996-04-04 2006-05-30 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US5994006A (en) 1996-06-04 1999-11-30 Nikon Corporation Projection exposure methods
US6106843A (en) 1996-12-10 2000-08-22 Council Of Scientific & Industrial Research Process for the isolation of a nontoxinogenic vibrio cholerae strain and a process for preparing cholera vaccine from said vibrio cholerae strain
US6258540B1 (en) 1997-03-04 2001-07-10 Isis Innovation Limited Non-invasive prenatal diagnosis
US6265169B1 (en) 1997-05-22 2001-07-24 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Method based on the use of bacteriophages for the detection biological molecules in biological samples
US6811982B2 (en) 1997-06-09 2004-11-02 University Of Southern California Cancer diagnostic method based upon DNA methylation differences
US6455249B1 (en) 1997-09-10 2002-09-24 National Institutes Of Health Method of amplifying DNA and RNA mismatch cleavage products
US6013486A (en) 1997-09-17 2000-01-11 Yale University Method for selection of insertion mutants
US6440705B1 (en) 1998-10-01 2002-08-27 Vincent P. Stanton, Jr. Method for analyzing polynucleotides
US6759195B1 (en) 1999-03-25 2004-07-06 University Of Maryland Biotechnology Institute Method of differential display of prokaryotic messenger RNA by RTPCR
US6531282B1 (en) 2000-05-30 2003-03-11 Oligotrail, Llc Multiplex amplification and analysis of selected STR loci
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US6835541B2 (en) 2001-01-26 2004-12-28 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
US7323336B2 (en) 2001-02-21 2008-01-29 Verenium Corporation Enzymes having alpha amylase activity and methods of use thereof
US7101663B2 (en) 2001-03-02 2006-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education PCR method
US7179600B2 (en) 2001-04-12 2007-02-20 Biocore Co., Ltd. Oligonucleotide chip composition and a method for analyzing a hepatitis C virus genotype using the composition
US7138506B2 (en) 2001-05-09 2006-11-21 Genetic Id, Na, Inc. Universal microarray system
US7262030B2 (en) 2001-05-09 2007-08-28 Virginia Commonwealth University Multiple sequencible and ligatible structures for genomic analysis
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
US7188030B2 (en) 2001-08-21 2007-03-06 Applera Corporation Automatic threshold setting for quantitative polymerase chain reaction
US7132587B2 (en) 2001-11-08 2006-11-07 Agency Of Industrial Science And Technology Non-autonomous transposon gene of rice, transformed plant and method of use
US7118867B2 (en) 2001-11-20 2006-10-10 Roche Diagnostics Corporation Quantitative multiplex PCR with high dynamic range
US7125673B2 (en) 2002-03-25 2006-10-24 Chun-Yang Fan CpG retrieval of DNA from formalin-fixed pathology specimen for promoter methylation analysis
US7282328B2 (en) 2002-09-20 2007-10-16 New England Biolabs, Inc. Helicase dependent amplification of nucleic acids
US7317111B2 (en) 2002-09-23 2008-01-08 Aries Associates, Inc. Green and orange fluorescent labels and their uses
US7058504B2 (en) 2002-11-26 2006-06-06 Navteq North America, Llc Method for organizing map data
US7250258B2 (en) 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
US20070059769A1 (en) 2004-03-05 2007-03-15 Ola Blixt High throughput glycan microarrays
US20070084997A1 (en) 2004-06-11 2007-04-19 Ngk Insulators, Ltd. Method of producing microarray
US7329493B2 (en) 2004-12-22 2008-02-12 Asiagen Corporation One-tube nested PCR for detecting Mycobacterium tuberculosis
US20070099198A1 (en) 2005-03-14 2007-05-03 California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US20070059765A1 (en) 2005-03-22 2007-03-15 Denong Wang Liposome-based microarray and methods of use thereof
US20070048749A1 (en) * 2005-08-30 2007-03-01 Chiung-Nien Chen Method for survival prediction in gastric cancer patients after surgical operation using gene expression profiles and application thereof
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
US20070202525A1 (en) 2006-02-02 2007-08-30 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
US9603651B2 (en) 2013-02-21 2017-03-28 Medtronic, Inc. Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms

Non-Patent Citations (102)

* Cited by examiner, † Cited by third party
Title
"ANTIBODIES, A LABORATORY MANUAL", 1999
"B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING", 1984
"CANCER BIOLOGY", 1987, OXFORD UNIVERSITY PRESS, pages: 20,21
"CULTURE OF ANIMAL CELLS: A MANUAL OF BASIC TECHNIQUE", 2005
"CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 2007
"GENE TRANSFER AND EXPRESSION IN MAMMALIAN CELLS", 2003
"GENE TRANSFER VECTORS FOR MAMMALIAN CELLS", 1987, COLD SPRING HARBOR LABORATORY
"GENETICS TN MEDICINE", 1991, W B SAUNDERS CO.
"IMMOBILIZED CELLS AND ENZYMES", 1986, IRL PRESS
"IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY", 1987, ACADEMIC PRESS
"METHODS IN ENZYMOLOGY", ACADEMIC PRESS, INC.
"MOLECULAR CLONING: A LABORATORY MANUAL", 2001
"NUCLEIC ACID HYBRIDIZATION", 1984
"OLIGONUCLEOTIDE SYNTHESIS", 1984
"PCR 2: A PRACTICAL APPROACH", 1995
"PHYSICIAN'S DESK REFERENCE", 1998, MEDICAL ECONOMICS
"TRANSCRIPTION AND TRANSLATION", 1984
"WEIR'S HANDBOOK OF EXPERIMENTAL IMMUNOLOGY", 1996
AL-HAJJ ET AL., PNAS, vol. 100, 2003, pages 3983 - 3988
BEAVEN; GOLDBERG, ONCOLOGY, vol. 20, no. 5, 2006, pages 461 - 470
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BULLOCK ET AL.: "TECHNIQUES IN IMMUNOCYTOCHEMISTRY", vol. 1, 1982, ACADEMIC PRESS
CHARD: "AN INTRODUCTION TO RADIOIMMUNOASSAY AND RELATED TECHNIQUES", 1986, ELSEVIER SCIENCE PUBLISHERS
CHOU ET AL., NUCLEIC ACIDS RESEARCH, vol. 20, 1992, pages 1717 - 1723
COTTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 4397
COTTON, MUTAT. RES., vol. 285, 1993, pages 125 - 144
DRESSMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 100, no. 15, 2003, pages 8817 - 8822
GASPARINI ET AL., MOL. CELL PROBES, vol. 6, 1992, pages 1
GHAFFARZADEHGAN ET AL., WORLD J. GASTROENTEROL, vol. 14, no. 41, 2008, pages 6376 - 6381
GHAFFARZADEHGAN KAMRAN ET AL: "Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance.", WORLD JOURNAL OF GASTROENTEROLOGY : WJG, vol. 14, no. 41, 7 November 2008 (2008-11-07), pages 6376 - 6381, XP002634968, ISSN: 1007-9327 *
GIBBS ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 2437 - 2448
GRIFFIN ET AL., BIOCHEM., vol. 38, 1993, pages 147 - 159
GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1874 - 1878
HAYASHI, GENET. ANAL. TECH. APPL., vol. 9, 1992, pages 73 - 79
HELLER, ANNU. REV. BIOMED. ENG., vol. 4, 2002, pages 129 - 153
HERMAN ET AL., PROC NATL ACAD SCI U.S.A., vol. 93, no. 13, 1996, pages 9821 - 9826
HOLLAND ET AL., PROC. NATL. ACAD. SCI., vol. 88, 1991, pages 7276 - 7280
HSIEH H -F ET AL: "Molecular studies into the role of CD44 variants in metastasis in gastric cancer", MOLECULAR PATHOLOGY, vol. 52, no. 1, February 1999 (1999-02-01), pages 25 - 28, XP002634969, ISSN: 1366-8714 *
HUSTON ET AL., PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883
INNIS ET AL., PROC NATL ACAD SCI U.S.A., vol. 85, no. 24, 1988, pages 9436 - 9440
JOHNSON ET AL., J. CLIN. ONCOL., vol. 21, no. 7, 2003, pages 1404 - 1411
KCLLCY, NUCLEIC ACIDS RCS., vol. 27, 1999, pages 4830 - 4837
KEEN ET AL., TRENDS GENET., vol. 7, 1991, pages 5
KELLER GISELA ET AL: "Molecular medicine of gastric adenocarcinomas.", EXPERT REVIEWS IN MOLECULAR MEDICINE, vol. 7, no. 17, 30 August 2005 (2005-08-30), pages 1 - 13, XP008136115, ISSN: 1462-3994 *
KELLEY ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 4830 - 4837
KOMHER ET AL., NUCL. ACIDS. RES., vol. 17, 1989, pages 7779 - 7784
KOSTER; COHEN ET AL., ADV. CHROMAT., vol. 36, 1996, pages 127 - 162
KOSTRIKIS, SCIENCE, vol. 279, 1998, pages 1228 - 9
KROL ET AL., BIOTECHNIQUES, vol. 6, 1988, pages 958 - 976
KUPPUSWAMY, PROC. NATL. ACAD. SCI., 1991
KWOH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 1173 - 1177
LANDEGREN ET AL., SCIENCE, vol. 241, 1988, pages 1077 - 1080
LEMAITRE ET AL., PROC. NATL. ACAD. SCI., vol. 84, 1987, pages 648 - 652
LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6553 - 6556
LIU ET AL., GENOMICS, vol. 25, no. 3, 1995, pages 674 - 81
LIZARDI ET AL., BIO/TCCHNOLOGY, vol. 6, 1988, pages 1197
M. MACPHERSON ET AL.: "PCR 1: A PRACTICAL APPROACH", 1991, IRL PRESS
M.L.M. ANDERSON: "NUCLEIC ACID HYBRIDIZATION", 1999
MARRAS, GENET. ANAL., vol. 14, 1999, pages 151 - 6
MARTIN: "REMINGTON'S PHARM. SCI.", 1975, MACK PUBL. CO.
MAXAM; GILBERT, PROC. NATL. ACAD. SCI. USA, vol. 74, 1997, pages 560
MCKEAGE ET AL., J. CLIN. ONCOL., vol. 201, 1997, pages 1232 - 1237
MUELLER ET AL., SCIENCE, vol. 246, 1988, pages 780 - 786
MYERS ET AL., NATURE, vol. 313, 1985, pages 495
MYRIAM ET AL., EMBO REPORTS, vol. 5, no. 8, 2004, pages 795 - 800
NEWTON ET AL., NUCL. ACIDS RES., vol. 17, 1989, pages 2503
NICKERSON ET AL., PROC. NATL. ACAD. SCI., 1990
NYREN ET AL., ANAL. BIOCHEM., vol. 208, 1993, pages 171 - 175
OCHMAN ET AL., GENETICS, vol. 120, 1988, pages 621 - 623
ORITA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2766
PAPAMICHEAL, THE ONCOLOGIST, vol. 4, 1999, pages 478 - 487
PAVLOV ET AL.: "Thermostable DNA Polymerases for a Wide Spectrum of Applications: Comparison of a Robust Hybrid TopoTaq to other enzymes", KIELECZAWA J: DNA SEQUENCING II: OPTIMIZING PREPARATION AND CLEANUP, 2006, pages 241 - 257
PIERCE ET AL., METHODS MOL. MED., vol. 132, 2007, pages 65 - 85
PRCZANT, HUM. MUTAT., vol. 1, 1992, pages 159 - 164
PROSSNER, TIBTECH, vol. 11, 1993, pages 238
ROSENBAUM; REISSNER, BIOPHYS. CHEM., vol. 265, 1987, pages 1275
SAIKI ET AL., NATURE, vol. 324, 1986, pages 163
SAIKI ET AL., NATURE, vol. 324, no. 6093, 1986, pages 163 - 166
SAIKI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6230
SALEEBA ET AL., METHODS ENZY., vol. 217, 1992, pages 286 - 295
SANGER ET AL., PROC. NAT. ACAD. SCI., vol. 74, 1977, pages 5463
SARIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 7448 - 7451
SHARKEY ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 506 - 509
SHUKLA SUNITA J ET AL: "Whole-genome approach implicates CD44 in cellular resistance to carboplatin.", PUBMED CENTRAL LIBRARY, 2009, pages 1 - 19, XP002634967, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683878/pdf/nihms110201.pdf> [retrieved on 20110504] *
SOKOLOV, NUCL. ACIDS RES., vol. 18, 1990, pages 3671
STCIN, NUCL. ACIDS RCS., vol. 16, 1988, pages 3209
STEMMER ET AL., GENE, vol. 164, no. 1, 1995, pages 49 - 53
SUGA ET AL: "Haplotype-Based Analysis of Genes Associated With Risk of Adverse Skin Reactions After Radiotherapy in Breast Cancer Patients", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, vol. 69, no. 3, 20 September 2007 (2007-09-20), PERGAMON PRESS, USA, pages 685 - 693, XP022261658, ISSN: 0360-3016, DOI: 10.1016/J.IJROBP.2007.06.021 *
SYVANEN ET AL., AMER. J. HUM. GENET., vol. 52, 1993, pages 46 - 59
SYVANEN ET AL., GENOMICS, vol. 8, 1990, pages 684 - 692
TAKAISHI ET AL., STEM CELLS, vol. 27, 2009, pages 106 - 1020
TIJSSEN: "PRACTICE AND THEORY OF IMMUNOASSAYS: LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY", 1985, ELSEVIER SCIENCE PUBLISHERS
TOBC, NUCLEIC ACIDS RES., vol. 24, 1996, pages 3728
TYAGI; KRAMER, NAT. BIOTECHNOL., vol. 14, 1996, pages 303 - 8
UGOZZOLI ET AL., GATA, vol. 9, 1992, pages 107 - 112
VOGELSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, no. 16, 1999, pages 9236 - 9241
WALLACE ET AL., NUCL. ACIDS RES., vol. 6, 1979, pages 3543
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WINDER T. ET AL: "Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma", INTERNATIONAL JOURNAL OF CANCER, vol. 129, 23 November 2010 (2010-11-23), XP002634970, DOI: 10.1002/ijc.25787 *
WU ET AL., GENOMICS, vol. 4, 1989, pages 560 - 569
ZIETKIEWICZ ET AL., GENOMICS, vol. 20, no. 2, 1994, pages 176 - 83
ZON, PHARM. RES., vol. 5, 1988, pages 539 - 549

Similar Documents

Publication Publication Date Title
US20120100997A1 (en) Cd133 polymorphisms and expression predict clinical outcome in patients with cancer
US20120100134A1 (en) Genetic variants in angiogenesis pathway associated with clinical outcome
WO2013172933A1 (fr) Profil génétique ethnique de gènes impliqués dans l&#39;angiogenèse pouvant prédire des différences régionales d&#39;efficacité du bévacizumab dans le cancer gastrique
WO2008089465A2 (fr) Polymorphismes géniques comme prédicteurs spécifiques au sexe dans la thérapie contre le cancer
US20110178110A1 (en) Genotype and Expression Analysis for Use in Predicting Outcome and Therapy Selection
US8216781B2 (en) Gene polymorphisms as predictors of tumor progression and their use in cancer therapy
US20100152202A1 (en) Tissue Factor Promoter Polymorphisms
US20120108445A1 (en) Vegf and vegfr1 gene expression useful for cancer prognosis
US20120100135A1 (en) Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
US20110160216A1 (en) Thymidylate Synthase Haplotype is Associated with Tumor Recurrence in Stage II and Stage III Colon Cancer Patients
WO2013172932A1 (fr) Gène suppresseur de tumeur de cancer du côlon, b-defensin 1, permettant de prédire la récurrence chez des patients atteints d&#39;un cancer du côlon au stade ii et iii
US20120094844A1 (en) Genetic variants in il-6, p53, mmp-9 and cxcr predict clinical outcome in patients with cancer
US20130023430A1 (en) Cancer stem cell gene variants are associated with tumor recurrence
US20120288861A1 (en) Germline polymorphisms in the sparc gene associated with clinical outcome in gastric cancer
WO2011085334A1 (fr) Polymorphismes du cd44 prédisant le résultat clinique chez des patients atteints d&#39;un cancer gastrique
US20110105529A1 (en) ERCC-1 Gene Expression Predicts Chemotherapy Outcome
US20140005064A1 (en) Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
WO2013172934A1 (fr) Variants génétiques d&#39;intégrine et récurrence de tumeurs spécifique au stade chez des patients atteints d&#39;un cancer du côlon au stade ii et iii
US20120107309A1 (en) Polymorphism in k-ras 3&#39; untranslated region associated with clinical outcomes of cancer treatments independent of k-ras mutation status
US20120289410A1 (en) Genetic variant in formyl peptide receptor 2 (fpr2) predicts clinical outcome in cancer patients
US20120289424A1 (en) Igf1r polymorphism predicts tumor recurrence in breast cancer patients
WO2011146406A1 (fr) Des polymorphismes de lignée germinale dans vegf prédisent des résultats cliniques chez des patients cancéreux traité avec le sorafénib
WO2011146411A1 (fr) Le polymorphisme du gène grp78 rs391957 est associé à une récurrence de tumeur et à la survie chez des patients atteints de cancer gastro-intestinal
WO2011146405A1 (fr) Les polymorphismes d&#39;egf +61g/a et ts 5&#39;utr 2r/3r prédisent les résultats cliniques chez des patients cancéreux recevant une thérapie anti-egfr
WO2013172922A1 (fr) Analyse du génotype lmtk3 destinée à être utilisée pour prédire le résultat et la sélection de la thérapie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11704338

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11704338

Country of ref document: EP

Kind code of ref document: A1